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Abstract 
THE EXPRESSION AND FUNCTION OF WILMS' TUMOR 1 IN MALIGNANT 
GLIOMA 
By Aaron J. Clark, B.S. 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2006 
Major Director: William C. Broaddus, M.D., Ph.D 
Hord Professor 
Department of Neurosurgery, Department of Anatomy and Neurobiology 
The Wilms' tumor 1 gene is overexpressed in many types of cancer and is 
associated with poor prognosis and resistance to anti-cancer therapies. In vitro studies in 
non-glioma cells types have demonstrated that WTl plays a role in increased proliferation, 
resistance to apoptosis, and increased cellular invasion. We aimed to thoroughly 
characterize the expression pattern of Wilms' tumor 1 in human malignant glioma and 
discern its function in this complex disease process. We screened a large sample of 
established human malignant glioma cell lines and glioma tissue specimens of all grades 
... 
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for WT1 expression. The majority of cell lines and 80% of all glioma tissue expressed 
WTI mRNA, all of which expressed WTl(+KTS) isoforms. Further screening of the 
glioblastoma specimens for p53 mutation followed by logistic regression analysis 
demonstrated a positive correlation between WTl expression and wild-type p53 ( p  = 0.04). 
To determine if WTl and p53 functionally interacted, we generated LN-229 glioblastoma 
cells that stably expressed WTl. As LN-229 cells harbor a p53 mutation, transient 
transfection with wild-type p53 induced apoptosis. However, stable WTI expression did 
not protect cells from p53-mediated cell death. We then generated U87MG cells (p53 
wild-type) that stably expressed WT1 to model an endogenous p53 response. It is well 
known that after treatment with ionizing radiation, U87MG cells readily undergo p53- 
mediated apoptosis. Again, WTI expression did not protect against ionizing radiation- 
induced p53-mediated cell death. We next examined the effect of transient WTI silencing 
on ionizing radiation induced cell death in T98G and LN-18 cells which express 
endogenous WTl. Combination treatment with ionizing radiation and silencing of WTI 
using short interfering RNA caused a decrease in viability and clonogenic survival relative 
to radiation alone in both cell lines. Lastly, we studied the effect of stable WTl silencing 
using short hairpin RNA on glioblastoma cell tumorigenicity. Stable transduction of 
U25 1MG and LN-18 cells with WTI short hairpin RNA resulted in a marked decrease in 
proliferation. WTI silencing in U251MG cells also caused a decrease in in vitro invasion. 
WTl silencing in U25 1 MG cells caused an increase in tumor latency and a decrease in 
tumor growth rate when cells were used to subcutaneously inoculate nude mice. Not only 
do these studies support an oncogenic role for WTI in glioma biology, they provide 
X 
encouraging evidence that WTl may be a therapeutic target for molecular treatment of 
glioblastoma. 
CHAPTER 1. 
INTRODUCTION 
THE OVERLAP BETWEEN GLIOBLASTOMA AND WILMS' 
TUMOR 1 BIOLOGY 
Abstract 
Glioblastoma is the most aggressive and most common primary brain tumor which, 
despite maximal treatment efforts, carries a poor prognosis. Numerous molecular changes 
have been characterized which may partially explain the extreme resistance of 
glioblastoma cells to surgery, radiotherapy, and chemotherapy. In spite of these advances 
in knowledge, a comparable increase in patient survival has not been attained. Further 
genetic characterization of these tumors promises to uncover additional targets for directed 
therapies which have the potential for use in combination with traditional therapies. One 
such gene may be the Wilms tumor I (WT1) gene. WTI has joined the ranks of a growing 
number of gene products critical for development and differentiation that become 
dysregulated during tumorigenesis. WTI is expressed in the normal developing central 
nervous system (CNS) and may play a role in neuronal differentiation. In the adult, WTl 
expression in the brain is restricted to the area postrema, but is aberrantly overexpressed in 
1 
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the majority of gliomas of all grades. Several physiologic and pathologic functions of 
WT1 suggest possible roles in glioblastoma, including trans-activation of growth factor 
and growth factor receptor genes, transcriptional regulation of cell cycle regulatory genes, 
interaction with the p53 tumor suppressor, and modulation of cell motility and invasion. 
Future study of WT1 in glioblastoma may establish its oncogenic role and its potential as 
an efficacious therapeutic target. Here we review malignant glioma clinical behavior and 
molecular genetics with an emphasis on pathways that may be modulated by WTl, the 
molecular biology of which is then extensively described. 
Brain tumor classification and grading 
Neuroectodermal tumors, whether arising in the central or peripheral nervous 
system, are classified according to the cell of origin, as determined by morphology and 
immunohistochemistry of the predominant cell type comprising the tumor. This 
classification system is largely based on the seminal work of Harvey Cushing and his 
colleague Percival Bailey in the early 1900's, who were investigating methods of 
correlating outcome with histology[l]. The gliomas are central nervous system 
neuroectodermal tumors of glial origin and include astrocytomas, oligodendrogliomas, 
mixed gliomas, ependymomas and a variety of other glial tumor types. Gliomas can arise 
throughout the brain, brain stem, and spinal cord, but most commonly occur in the deep 
white matter of the cerebral hemispheres[l]. Because gliomas rarely metastasize outside 
of the central nervous system (CNS), staging of these tumors is not performed[l84]. 
Rather, gliomas are graded I - IV according to the histological determination of 
malignancy described by the World Health Organization (WHO) grading system[l04]. 
The WHO grading system is based on the presence of nuclear atypia, vascular 
proliferation, mitotic figures, and necrosis[l]. Grade I gliomas are benign, well- 
circumscribed, and often curable tumors while grades I1 - IV correspond to increasingly 
malignant and invasive tumors that prove difficult to eradicate. 
Epidemiology of brain tumors 
Primary brain tumors of all grades, when considered as a group, are a relatively rare 
type of tumor with an incidence rate of 14.8 cases per 100,000 person-years, according to 
the Central Brain Tumor Registry of the United States[27]. In 2005, an estimated 43,800 
brain tumors were diagnosed in the United States. However, brain tumors are very 
prevalent in certain populations and responsible for significant morbidity. They are the 
most common solid tumor in children ages 0 - 19 and the second most common cancer 
following leukemia in this age group. They were also the leading cause of cancer death 
among children and young adult men ages 20 - 34 in 2000. Malignant primary brain 
tumors constitute a large proportion of all primary brain tumors and therefore have a high 
mortality rate. It is estimated that 21,690 primary brain tumors diagnosed in 2005 will be 
malignant causing an estimated 12,760 deaths. 
Epidemiolow of glioblastoma 
The gliomas account for 40% of all primary brain tumors[27]. The diffuse 
astrocytomas comprise more than 80% of the gliomas and include grade I1 astrocytoma, 
anaplastic astrocytoma (grade 111), and glioblastoma (grade IV). Anaplastic astrocytoma 
and glioblastoma are often collectively referred to as the malignant gliomas. In addition to 
being the most deadly brain tumor, glioblastoma is also the most common primary 
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malignant brain tumor accounting for 20.3% of all primary brain tumors and 50.7% of 
gliomas. The incidence of glioblastoma increases with age with a median age at diagnosis 
of 64. Incidence rates of glioblastoma are 1.6 times higher in males than females and 2 
times higher in whites than blacks[l71]. Although the cause is unknown, the incidence of 
glioblastoma appears to have increased between 1977 and 2000, particularly in the 
elderly[82]. 
In spite of high quality ep@emiologic data, few risk factors and predisposing 
conditions have been definitively identified. Whole brain radiation during childhood is the 
only known risk factor for sporadic glioma. A large cohort of children treated for acute 
lymphoblastic leukemia (ALL) was retrospectively analyzed for development of secondary 
neoplasms[l69]. Nearly half of all secondary neoplasms were malignant gliomas and all 
occurred in children who had received cranial radiation. These results could be interpreted 
to indicate an interaction between DNA damaging therapies and underlying genetic 
predispositions to cancer. In fact, several genetic syndromes include predisposition to 
glioma development and the tumor suppressor genes involved provide clues to their role in 
sporadic gliomagenesis[l49]. The hereditary tumor syndromes neurofibromatosis types 1 
and 2, tuberous sclerosis con~plex, Li-Fraumeni syndrome, melanoma-astrocytoma 
syndrome, and Turcot syndrome include predisposition to glioma formation. 
Neurofibromatosis type 1 and tuberous sclerosis complex predispose to optic glioma and 
subependymal giant cell astrocytomas, respectively, both generally benign tumors while 
the others confer risk of diffuse astrocytoma development including glioblastoma. The 
mutations underlying these syndromes and their propensity for development of glioma 
5 
demonstrates the importance of molecular pathways which will be mentioned here and 
discussed in more detail below (please see "Glioblastoma molecular biology"). 
Neurofibromatosis type 1 is caused by germ line mutation of the tumor suppressor NF1. 
Its tumor suppressive function derives from its ability to maintain the proto-oncogene Ras 
in an inactive GTP-bound state, as demonstrated by observational studies in tumor cell 
lines derived from NFl tumor specimens[41]. In sporadic gliomagenesis, Ras is a critical 
downstream transducer of growth factor receptor mediated signaling. Li-Fraumeni 
syndrome is caused by mutation of the tumor suppressor p53, which is mutated or 
otherwise functionally inactivated in a significant proportion of sporadic gliomas[l39]. 
P53 exerts its function by inducing cell cycle arrest and/or apoptosis in response to DNA 
damage, including oncogenic mutations[l32]. Melanoma-astrocytoma syndrome is 
associated with loss of the CDKN2A locus which encodes two tumor suppressors; p16 INK4a 
INK4a and pl 9ARF, both of which are commonly lost in sporadic glioblastoma[9]. P16 is 
responsible for maintaining the retinoblastoma (Rb) tumor suppressor in an active state, 
while p l  9ARF functions by preventing p53 degradation. Familial glioma syndromes have 
also been reported in the absence of other tumor predisposition syndromes but the 
causative lesion is unknown. 
Clinical features, prognosis, and treatment of glioblastoma 
The classically described triad of symptoms for glioblastoma on presentation are; 
headache, seizure, and hemiparesis. The preliminary diagnosis of glioblastoma is 
generally made by identification of characteristic radiographic features. Biopsy and 
subsequent histologic classification are required for definitive diagnosis. Diagnosis of 
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glioblastoma confers a poor prognosis with a median survival of approximately 1 year and 
a five year survival is less than 4%[27, 1481. Analysis of over 1500 patients enrolled in 
Radiation Therapy Oncology Group clinical trials demonstrated that prognosis within this 
narrow range is predicted by age, histology, Karnofsky Performance Scale (KPS) score, 
mental/neurologic status, extent of surgical resection, and dose of radiation[2 141. 
Specifically, younger age, less malignant histology, higher KPS score and neurologic 
function, and more aggressive treatment are associated with improved prognosis. 
Recently, microarray analysis of a large sample of malignant gliomas followed by 
classification based on gene expression profiles was shown to better predict survival than 
histopathologic analysis[l70]. A similar study found that gene expression profiling based 
on microarray analysis of tumor tissue extracts identified novel genes associated with 
prognosis that were superior to the predictive power of established glioma-associated 
genetic changes[l99]. These findings suggest that complete molecular characterization of 
gliomas may improve prognosis prediction. The genetic analysis of long term survivors 
(those surviving greater than 3 years, LTS) is intriguing as survival past three years is 
associated with extended disease-free survival[21]. Comparative genomic hybridization 
was used to compare genetic changes in LTS tumors compared with those patients 
surviving less than 1.5 years. Loss of chromosome 19q was associated with LTS in this 
study[21]. Studies such as these highlight the importance of such analyses not only in 
distinguishing different prognostic groups but also by identifying changes that determine 
disease progression. Future treatments may feature standard therapy supplemented with 
targeted molecular therapies based on the results of such studies. Current standard of care 
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for patients with glioblastoma is surgical resection followed by radiotherapy and adjuvant 
chemotherapy. 
Surgery for glioblastoma 
The goals of surgery for glioblastoma are relief of neurologic symptoms caused by 
the expanding mass, obtaining a definitive diagnosis, and cytoreduction[235]. Aggressive 
surgery for glioblastoma is controversial as wider margins of resection carry the risk of 
inducing iatrogenic neurologic deficits. However, studies have shown that open 
craniotomy for tumor resection yields superior survival relative to biopsy alone[ll3]. In 
addition, extent of resection improves survival suggesting that cytoreduction of malignant 
cells is crucial for disease contro1[224, 1 181. Glioblastoma cell invasiveness remains the 
major obstacle to eliciting a surgical cure. In 196 1, Matsukado et a1 reviewed 100 
necropsy specimens and showed that 4711 00 had invaded the corpus collosum to involve 
both cerebral hemispheres, demonstrating the classic "butterfly glioma" pattern[l42]. 
Most agree that these tumors cannot be completely resected. Furthermore, with the 
exception of tumors located in the tip of the frontal lobe, all tumors that involved a single 
hemisphere had spread into adjacent lobes. Microscopically, tumor cells were present 
beyond the gross demarcation between tumor and normal tissue. A more recent study 
demonstrated that, in a significant number of glioblastoma specimens (311 5), tumor cells 
were detected at autopsy more than 2 cm outside the enhancing margin shown on 
computerized tomography (CT) scans[20]. Taken together, this study indicates that 
invading cells make gross total resection, even when utilizing intraoperative CT image 
guidance systems, difficult and, in nearly half of cases, impossible. In the fbture, 
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cytoreductive surgery combined with molecular targeting of residual invading cells may 
improve prognosis. The molecular biology of glioma invasion and potential therapeutic 
anti-invasive targets are described in more detail below (please see "Molecular biology of 
glioma invasion"). 
Chemotherapy for glioblastoma 
Chemotherapy is a component of standard glioblastoma treatment and modestly 
improves 1 and 2 year survival by approximately 5%[227]. Alkylating agents are the most 
commonly used chemotherapeutic agents used in the treatment of malignant gliomas which 
induce DNA damage by covalently attaching an alkyl group to the o6 position of guanine. 
Of these 1,3-bis(2-chloroethy1)- 1 -nitrosourea (BCNU) has been the most commonly used 
since it was first described to improve survival when compared to patients who received no 
chemotherapy and no radiotherapy[252]. Alternative methods of delivery to bypass the 
blood-brain-barrier, such as BCNU-impregnated implantable polymers, are also employed, 
and in certain subgroups of patients may improve surviva1[262]. 
Temozolamide (TMZ), a second generation imidazotetrazine pro-drug which is 
physiologically converted to an alkylating agent, has a more favorable therapeutic profile 
than BCNU and has become the chemotherapy agent of choice[l93]. TMZ, an oral agent, 
crosses the blood-brain barrier and exhibits limited systemic toxicity. Furthermore, TMZ 
improves progression-free survival by 13% at six months in patients with recurrent 
glioblastoma[269]. When combined with radiotherapy, TMZ increases median survival 
relative to radiotherapy alone[228]. The DNA repair enzyme 0 6 - m e t h y l g u a n i n e - ~ ~ ~  
methyltransferase (MGMT) is primarily responsible for removal of alkyl groups from 
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DNA and, therefore, is involved in resistance to alkylating agents in glioblastoma[l07]. 
Patients with methylation of the MGMT promoter, and subsequent silencing of the mgmt 
gene, have a significant survival benefit from TMZ combined with radiotherapy relative to 
those without methylation underscoring the importance of molecular characterization of 
glioblastoma in optimizing treatment[79]. 
Radiotherapy for glioblastoma 
In the treatment of glioblastoma, radiotherapy is used post-operatively in 
combination with chemotherapy. Ionizing radiation induces DNA damage by directly 
damaging the DNA molecule and indirectly by generating oxygen free radicals from water 
molecules, which leads to apoptosis. While normal cells undergo apoptosis in response to 
ionizing radiation, glioblastoma cells are notoriously resistant to apoptosis by molecular 
mechanisms which will be described below[219]. Therefore, although escalating doses of 
radiotherapy increase survival, radiotherapy is not curative[253]. Nevertheless, surgery 
followed by radiotherapy improves survival when compared to surgery alone[252]. 
Current therapy consists of a total dose of 50 - 60 Gy in thirty 1.8 - 2.0 Gy fractions 
targeting the entire enhancing tumor mass plus a 2 cm margin[l I]. In spite of numerous 
large clinical trials, alternative delivery schedules, hyperthermia, particle therapy, and 
radiosensitizers have not been shown to improve survival relative to conventional 
fractionated radiotherapy[l20]. The majority of glioblastomas recur within 2 cm of the 
original tumor site, in one study even after delivery of a 14 Gy boost to this area, 
suggesting the presence of residual tumor cells near the resection cavity that are capable of 
resisting apoptosis induced by adjuvant radiotherapy[56]. Therefore studies focused on 
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improving the apoptotic response of residual tumor cells to radiotherapy become critical in 
the search for a cure. Such in~provements may come from identification of molecular 
changes in glioma that confer a resistant phenotype. 
Glioblastoma molecular biology 
The ability of glioblastoma cells to resist DNA damaging therapies suggests that 
glioblastoma cells possess inherent resistance to DNA-damage induced cell death. 
Specific molecular changes may explain this extreme resistance. In addition, molecular 
mechanisms supporting cell invasion may allow tumor cells to disseminate widely enough 
to evade surgical resection. Full molecular characterization of glioblastoma promises to 
provide the basis for targeted molecular therapies that will complement the traditionally 
employed modalities described above. 
Glioblastoma can be divided into two subgroups based on clinical history; primary 
and secondary glioblastoma. Cytogenetic and molecular examination of the two subgroups 
of glioblastoma provides clues to central mechanisms underlying gliomagenesis and 
glioblastoma behavior. Primary glioblastoma arises de novo without evidence of a less 
malignant precursor tumor, occurs in older age groups, and is rapidly progressive with a 
clinical history of less than three months. Secondary glioblastoma arises from a pre- 
existing lower grade glioma, occurs in younger patients with the progression to grade IV 
glioblastoma over 5 - 10 years. However, once diagnosis of glioblastoma is established, 
the prognosis and histology of the tumors are indistinguishable. In addition to differences 
in clinical history, these tumors can be distinguished by characteristic genetic 
aberrations[258]. Primary glioblastoma possesses amplification of the receptor tyrosine 
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kinase (RTK) epidermal growth factor receptor (EGFR)[258], murine double minute 2 
(MDM2) amplification[21 I], mutation of the phosphatase PTEN[234], and deletion of 
p161NK4a [241]. Secondary glioblastoma is characterized by mutation of the p53 tumor 
suppressor[258], loss of heterozygosity (LOH) on chromosome 10q[l19], and 
overexpression of the RTK platelet-derived growth factor (PDGF) receptor and its ligand 
PDGF[71]. Although the exact mutations are different between primary and secondary 
glioblastoma, the pathways affected are similar; receptor tyrosine kinase-activated 
pathways, and the tumor suppressor Rb- and p53-mediated pathways. As critical to both 
primary and secondary glioblastoma, these pathways represent targets of action of 
aberrantly expressed oncogenes in addition to being functional targets for novel 
therapeutics. 
Receptor tyrosine kinases 
RTKs dimerize in response to ligand binding, undergo autophosphorylation, and 
recruit adapter proteins which activate downstream effectors, such as the proto-oncogene 
Ras. EGFR is amplified in approximately 40% of primary glioblastomas leading to 
overexpression of the receptor[l25]. Of those that overexpress EGFR, 40% are termed 
EGFRvIII and possess a deletion of exons 2 - 7 which encodes the extracellular ligand 
binding domain, thus resulting in constitutive activation[86]. Activated EGFR, either by 
ligand binding or activating mutations, stimulates downstream Ras/Raf/MEK/MAP kinase 
and PI3 kinase/AKT signal transduction pathways, which are involved in cell proliferation, 
survival, and invasion[97]. EGFRvIII increases the tumorigenicity of glioblastoma cells 
both in vitro and in vivo, by increasing proliferation rate and decreasing apoptosis[l64]. 
12 
EGFRvIII expression also increases the chemoresistance of glioma cells[165]. Both of 
these observations are associated with increases in the anti-apoptotic Bcl-2 family member, 
Bcl-XL[165, 1641. Additionally, EGFRvIII increases the in vitro invasiveness of 
glioblastoma cells, possibly due to up-regulation of several invasion related genes which 
will be discussed in more detail below, including matrix metalloproteinases (MMPs) and 
extracellular matrix (ECM) molecules(p1ease see "Molecular biology of glioma 
invasionm)[l 171. Specifically relevant to the treatment of glioblastoma, EGFR expression 
strongly correlates with resistance to radiotherapy in a large clinical study[lO]. 
PDGFR and PDGF ligands are co-expressed in the same glioblastoma cells 
suggesting an autocrine stimulatory loop[71]. Ligand binding to PDGFR activates the 
same pathways as EGFR (i.e. MAPK and PI3K pathways) [218]. PDGF and PDGFR 
overexpression represent early changes in glioma progression and therefore may play a 
role in glioma development. In a large sample of low grade gliomas, PDGFR was 
overexpressed in 50% and expression correlated with progression to high grade glioma 
highlighting its role in secondary glioblastoma[247]. Mouse models provide clues as to 
the function of PDGF in glioma progression. Artificial expression of PDGF in mouse 
models induces the formation of oligodendrogliomas, however if AKT signaling is also 
perturbed, astrocytomas form, underscoring the complexity of signaling pathways leading 
to glioblastoma[36]. In addition to its role in glioma development, evidence indicates that 
PDGF signaling continues to play a role in glioblastoma. Treatment of several 
glioblastoma cell lines with specific PDGFR inhibitors decreased clonogenicity and tumor 
growth in nude mice[l30]. PDGF signaling also contributes to glioma neovascularization, 
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an important component of glioblastoma tumorigenicity, by stimulating vascular 
endothelial growth factor (VEGF) expression in tumor endothelial cells and subsequent 
endothelial proliferation[72]. Therefore, PDGF not only has autocrine function, but also 
paracrine action on tumor associated blood vessels. Most importantly, nude mice 
harboring glioma xenografts respond to the orally active specific PDGFR tyrosine kinase 
inhibitor, Gleevec (Imatinib) which is currently being used clinically to treat other types of 
human cancers[lOl]. This has prompted a clinical trial to examine the efficacy of this 
inhibitor in the treatment of glioblastoma. Although clearly important in gliomagenesis, 
the mechanism of overexpression of PDGF is currently unknown. 
Through either LOH on the long arm of chromosome 10 (secondary glioblastoma) 
or mutation (primary glioblastoma), the phosphatase and tensin homology gene (PTEN) is 
inactivated in the majority of malignant gliomas[l19,234]. PTEN is a 3' phosphoinositol 
phosphatase that dephosphorylates PIP3, a second messenger involved in PI3KlAKT 
signaling, thus acting as a negative regulator of the pathway. Loss of PTEN allows 
constitutive activation of AKT leading to cell proliferation, survival, and development of 
glioblastoma. Mutations in downstream effects of RTK represent alternative mechanisms 
of stimulating tumor cell growth and resistance. 
Retinoblastoma (RB) pathways 
The gene encoding the tumor suppressor Rb is mutated in approximately 30% of 
malignant gliomas[80]. Un-phosphorylated Rb binds E2F, inhibiting transcription of 
genes involved in cell cycle progression. In response to growth promoting stimuli, Cyclin 
Dl is activated which in turn activates cyclin-dependent kinase (CDK) 4 and 6, which 
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phosphorylate Rb. Rb releases E2F which transactivates target genes leading to mitosis 
and progression through the G1 checkpoint. The CDK inhibitor p161NK4A inhibits CDK 4 
and 6, preventing phosphorylation of Rb and maintaining cells in a quiescent state. 
Inactivation of p1 6'NK4A occurs in 50% of primary glioblastoma and represents an 
alternative mechanism of inactivating the Rb tumor suppressor, leading to unregulated 
growth[24 1 1. 
p53 pathways 
Mutations in the gene encoding the p53 tumor suppressor occur in 33% of human 
glioblastomas and are more common in secondary glioblastoma. The most common 
mutations in gliomas occur at codons 273,248, and 175 in order of decreasing 
frequency[l2]. Tetramerization is required for wild-type p53 function which is attributed 
to a C-terminal oligomerization domain. Therefore, mutant p53 can exert dominant 
negative effects by oligomerizing with wild-type p53. Its tumor suppressor function is 
intimately tied to its function as a transcription factor. DNA damage, including oncogenic 
mutations, activates p53 which directly initiates cell cycle arrest and apoptosis by 
WAF 1 transactivation of downstream target genes, most importantly the CDK inhibitor, p2 1 , 
and the pro-apoptotic Bcl-2 family member, Bax, respectively[45, 1581. More recent 
studies show that p53 is critical for autophagy, senescence, DNA repair, and 
differentiation, all of which are consistent with tumor suppression[33, 65, 2711. 
Normal cells possess low levels of p53 due to its short half life[5]. The ubiquitin 
ligase MDM2 targets p53 for proteasomal mediated degradation and is the most important 
mechanism of inactivation of p53[78]. As such, it is amplified in 13% of primary 
15 
glioblastomas[211]. Interestingly, the same study showed that MDM2 amplifications are 
mutually exclusive with p53 mutations suggesting it is one specific mechanism for 
inactivating wild-type p53. Given the central role of p53 in tumor suppression and 
sensitivity to DNA damaging therapies, glioma cells which possess wild-type p53 in the 
absence of MDM2 amplification must harness alternative mechanisms of evading the p53 
response. 
As expected based on its role in response to DNA damage, p53 plays a key role in 
response to radiotherapy. Adenoviral transduction of p53 mutant glioma cell lines with 
wild-type p53 induces virtually 100% apoptosis within 4 - 8 days[68]. Stable transfection 
of p53 into p53 mutant glioma cells decreases clonogenic survival after radiotherapy[66]. 
In vivo adenoviral transduction of mutant p53 gliosarcoma cells with wild-type p53 causes 
reduction in tumor size and increased survival when combined with radiotherapy[8]. Pro- 
apoptotic downstream targets of p53 are critical to a successful apoptotic response to 
radiotherapy. Wild-type p53 glioma cell resistance to radiotherapy demonstrated by lack 
of ionizing radiation-induced apoptosis correlates with lack of Bax induction[2 191. 
Adenoviral transduction of p53 mutant glioma cell lines with Bax increases sensitivity to 
fractionated radiotherapy by inducing both in vitro apoptosis and in vivo tumor regression 
in nude mice[6]. These results indicate that functional inactivation of wild-type p53 may 
lead to a defect in Bax activation and therefore may explain glioma radioresistance. 
In the response to radiotherapy, functional inactivation of p53 in glioma cells may 
be achieved by decreased expression of Ataxia Telangiectasia Mutated (ATM), which 
phosphorylates and activates p53 in response to DNA damage. In a study of a small 
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sample of primary glioblastoma cultures, lower levels of ATM expression correlated with 
increased clonogenic survival after irradiation[237]. Our laboratory has shown that 
adenoviral transduction of glioma cells that possess wild-type p53 with additional wild- 
type p53 can decrease radioresistance suggesting the supraphysiologic levels of p53 can 
overcome functional inactivation[l4]. A complete understanding of the mechanisms of 
functional inactivation of p53 in glioblastoma promises to uncover novel therapeutic 
targets to increase apoptosis and decrease resistance to radiotherapy. 
Molecular biolog~ of glioma invasion 
In addition to increased proliferation and resistance to therapy, glioma cell invasion 
is also a key component of tumorigenicity. The most provocative illustration of the 
extreme invasiveness of glioma cells is the observation that these tumors recur even after 
radical resections such as hemispherectomy of the affected cerebral hemisphere. This 
underscores the concept that, even after wide margin resection of a glioblastoma, tumor 
cells invading grossly normal appearing brain can cause recurrence and death[221]. It has 
long been recognized that glioma cells preferentially invade along vascular basement 
membranes in Virchow-Robins spaces, white matter tracts, and the subependymal zone 
suggesting that factors, such as ECM components, present in defined areas of the brain 
promote tumor cell migration[l42]. Glioma cell invasion requires a complex interaction 
between the ECM and the cell. In point of fact, the first step in glioma invasion involves 
adhesion of the cell to ECM components. Exposure of glioma cells to the ECM 
components fibronectin, collagen IV, tenascin-C, vitronectin, and laminin stimulates 
migration[l35, 621. In addition, glioma cells can modulate the ECM by secreting ECM 
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components which can lead to increased adhesion ultimately enhancing invasion[63]. The 
major cellular mediator of adhesion is the intergrin family which is comprised of 
heterodimeric glycoproteins formed by various combinations of different a and P chains. 
Up-regulation of pl integrin in C6 glioma cells causes diffuse invasion when implanted in 
the brains of nude mice[186]. Conversely, in vitro invasion of glioma cells is blocked after 
treatment with anti-pl antibodies[63]. The second step is cell movement which involves a 
reorganization of the actin cytoskeleton resulting in a polarized cell with lamellopodia in 
the invading front end and a retracting rear end[259]. 
The third step is invasion into an intercellular space created by the secretion of 
ECM degrading proteases, in particular the MMPs. The MMPs are a multigene family 
subdivided into groups based on their substrate specificity. Membrane type 1 -MMP 
(MT1 -MMP), MMP-1, MMP-2, and MMP-9 are overexpressed in gliomas and are the 
most well studied of the family[245, 146, 50, 1671. Levels of MMP activity increases with 
increasing grade, being highest in glioblastoma, and may play a role in 
aggressiveness[l67]. They are normally tightly regulated to maintain activity only when 
needed for functions such as wound healing, angiogenesis, and axonal growth cone 
extension. The MMPs are regulated at the transcriptional level and are often up-regulated 
in response to growth factor stimulation[201]. Results from our laboratory show that a 
single nucleotide polymorphism (SNP) in the MMP-1 promoter which creates a binding 
site for ETS transcription factor family members leads to increased MMP-1 expression in 
glioblastoma[l46]. The MMPs are secreted as inactive zymogens and require cleavage for 
activation, thus introducing a second layer of regulation. Our laboratory has shown that 
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EGF stimulation can cause up-regulation of MTl-MMP, which activates MMP-2 and 
subsequently increases in vitro invasiveness[244]. MMP-2 and MTl -MMP are often 
expressed in the same cell providing a mechanism by which the cell can directly activate 
its secreted pro-MMP-2 by MTl -MMP in the cell membrane[50]. MMP-9 is expressed by 
endothelial cells at the invading edge of glioblastoma and may be involved in the ingrowth 
of oxygen supplying tumor vasculature into the rapidly growing tumor[50]. Third, 
naturally occurring tissue inhibitors of MMPs (TIMPs) inhibit the enzymatic activity. 
TIMP-1 expression is under-represented in glioblastoma suggesting a mechanism of 
increased invasion[l67]. Transfection of a highly invasive glioma cell line that expresses 
low endogenous levels of TIMPs with TIMP-1 causes a decrease in invasion[l43]. 
The concept behind adjuvant therapies following surgery such as radiotherapy and 
chemotherapy impregnated wafers deposited in the tumor resection cavity is to target 
residual invading tumor cells. Recent evidence suggests that certain characteristics of 
invading cells may confer resistance to such therapies. DNA damaging therapies, such as 
ionizing radiation and chemotherapy, target rapidly proliferating cells. However, glioma 
cells selected for migration ability proliferate more slowly when plated on glioma-derived 
ECM[147]. Decreased proliferation of invasive cells may be due to decreases in 
expression of cell cycle regulatory proteins such as Cyclin A and B after exposure to ECM 
proteins[l41]. Therefore, more slowly dividing invading cells may resist DNA damaging 
therapies leading to regrowth and recurrence. Furthermore, glioma cells stimulated to 
migrate by ECM components down-regulate pro-apoptotic genes while up-regulating anti- 
apoptotic genes[l41]. Also relevant to choice of therapy is the surprising observation that 
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inhibition of tumor angiogenesis with a monoclonal antibody against the VEGF receptor 
decreased tumor growth but caused dramatically increased invasion of glioma cells along 
host blood vessels eventually leading to leptomeningeal spread[ll2]. These results 
demonstrate the interrelatedness of glioma molecular pathways and the importance of 
understanding and targeting several pathways when treating malignant gliomas. 
Wilms ' tumor 1 and glioblastoma 
In search of novel genes involved in glioma biology, our laboratory performed 
exploratory studies examining the expression of Wilms' tumor 1 (WT1) in glioblastoma 
cell lines. We reported that 417 established glioma cells lines overexpressed WT 1 [19 11. 
Subsequently, we and several other groups demonstrated WT1 overexpression in larger 
samples of glioma cells lines and glioblastoma tissue specimens[l52, 43, 178, 168, 301. 
The function of WTl in these tumors is currently unknown. Evidence based on the known 
physiologic and pathologic function of WTl which will be extensively discussed below 
suggests many potential mechanisms of WTl function in glioblastoma. 
Wilms' tumor 
In 1899, Dr. Carl Max Wilms, a renowned German surgeon, comprehensively 
reviewed childhood renal cancer in his book Die Mishgeschewulste der Niere. Due to his 
thorough description of the disease and the correct assertion as to the cell of origin of the 
tumor, the malignancy that he described, nephroblastoma, is now known as Wilms' 
tumor[32]. Wilms' tumor, for which WTl is named, is the most common pediatric kidney 
cancer with a median age at diagnosis of 3.5 years[l3]. Overall, it accounts for 6% of 
pediatric malignancies[73]. The majority of Wilms' tumors are solitary, however 6% are 
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bilateral and 12% are multifocal. Wilms' tumors metastasize to the lungs most commonly, 
followed by the lymph nodes and liver, rarely to the bone and brain. Patients typically 
present with an asymptomatic abdominal mass that is palpable on physical examination. 
Current standard of care in North America involves nephrectomy followed by 
chemotherapy with or without radiotherapy depending on the stage of disease[70]. In 
contrast to GBM, survival has improved from 30% in the 1930's to greater than 85% in the 
present day. Studies now focus on tailoring therapies to cure the disease while sparing the 
patient from the side effects of systemic therapy. 
Wilms' tumor 1 (WT1) structure and function 
Knudson and Strong reviewed a large number of case studies and proposed a two- 
hit model for Wilms' tumorigenesis, similar to that of retinoblastoma in which inactivation 
of both alleles of a tumor suppressor gene were necessary for tumor formation[l06]. 
Cytogenetic analysis of individuals with WAGR syndrome (Wilms' tumor predisposition, 
Aniridia, Genitourinary malformations, mental Retardation) implicated mutation in 
chromosome 1 lp13 in the development of Wilms' tumor[53, 671. The region was also 
observed to be mutated in sporadic Wilms' tumors, thus potentially harboring a tumor 
suppressor[l08]. Subsequent examination of Wilms' tumor cell lines and embryonic tissue 
led to the isolation of a transcript from this region[23, 591. This gene was shown to be 
mutated in approximately 6% of sporadic Wilms' tumors and was named Wilms' tumor 1 
(WT1)[59,246, 1261. As confirmatory evidence, WTl was found to be mutated in patients 
with Denys-Drash syndrome, which consists of renal failure, pseudohermaphroditism, and 
Wilms' tumor[187]. To date, WTl is the sole gene demonstrated to be involved in the 
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development of Wilms' tumor. Several characteristics of WT1 biology suggest that it may 
be important in glioblastoma behavior. 
The wtl  gene is composed of 10 exons approxin~ately 50 kb in length and encodes 
a 3.1 kb transcript[58, 231. Alternative splicing generates four major isoforms depending 
on the inclusion or exclusion of 5 1 nucleotides encoded by exon 5 and nine nucleotides in 
exon 9, known as KTS[75]. WT1 (+I+) contains both exon 5 and KTS, WT1 (+I-) contains 
exon 5 but lacks KTS, WT1(-I+) lacks exon 5 but contains KTS, and WTl(-I-) lacks both 
exon 5 and KTS (Figure 1 - 1). 
Figure 1-1. Schematic representation of the four major protein isoforms of WT1 with 
corresponding nomenclature. Gray boxes denote the two alternatively spliced exons; 
exon 5 and KTS in exon 9. 
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The WT1 protein has a molecular mass of 52 - 54 kDa, depending on the isoform[l62]. 
RNA editing converts uridine at the 839 position to cytosine, resulting in a change in 
codon 280 from leucine to proline[216]. Translation from an in-frame CUG upstream of 
the major WT1 start site generates novel 60 - 62 kDa WT1 isoforms[l8]. Translation 
initiated at a downstream AUG generates N-terminally truncated WT1 isoforms of 36 - 38 
kDa[208]. Both larger and smaller WT1 isoforms are expressed in human tissue and retain 
transcriptional activity. Thus, the number of WT1 isoforms characterized is 24. Both 
larger and smaller isoforms are expressed at lower levels and are less prevalent than the 4 
major WT1 isoforms and are, therefore, less well studied[l8, 2081. Furthermore, studies 
examining WT1 isoforms generated from the upstream CUG demonstrate that inclusion of 
the extended N-terminus does not modify the function relative to the corresponding major 
isoform[l8]. 
WTl is a transcription factor that contains an N-terminal proline and glutamine rich 
region and four C-terminal Cys2-His2 zinc fingers[23, 591. The proline-glutamine-rich 
region mediates homodimerization and transcriptional activation[l95,257]. Zinc fingers 2 
- 4 share 6 1 % homology with the early growth response- 1 (EGR- 1) transcription factor and 
all four are involved in DNA binding[23, 1921. The zinc fingers also contain two nuclear 
localization signals required for trafficking to the nucleus[l7]. As expected based on the 
structural similarities, WT1 binds to the GC-rich EGR-1 consensus sequence[l92]. In 
addition, WT1 binds to unique promoter sequences; TCC repeat motifs and a high affinity 
binding site referred to as WTE[256, 1661. As would be expected of a transcription factor 
involved in cancer development, WTl transcriptionally regulates the expression of several 
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growth regulatory genes including the CDK inhibitorp21 WAF' and cyclin E[49, 1291. WT1 
also up-regulates the expression of PDGF-A[255], which is of particular interest to 
glioblastoma biology for reasons which have been outlined above. WT1 also represses 
transcription of the anti-angiogenic factor, Thrombospondin-1 (TSP-1) in FR3T3 
immortalized rat embryonic fibroblast cells[42]. In a separate study, antisense induced 
WT1 knock-down caused decreased clonogenicity which was associated with up- 
regulation of TSP-1 in HL-60 leukemia cells[198]. This also is potentially relevant to 
glioblastoma because TSP- 1 expression in glioblastoma xenografts decreases growth rate 
and vascularity[l09]. At the transcriptional level, WT1 may play a role in glioma biology 
by modulating the cell cycle, growth factor-induced proliferation and survival, and 
angiogenesis. 
Alternative splicing of exon 9 inserts three amino acids, lysine-threonine-serine 
(KTS), in the linker sequence between zinc fingers 3 and 4[75]. Nuclear magnetic 
resonance analysis indicates that inclusion of KTS decreases the affinity of WTl for 
DNA[l 151. This is explained by studies which show the increased length of the linker 
caused by inclusion of KTS increases the flexibility between zinc fingers 3 and 4 that 
prevents binding of zinc finger 4 to DNA[116]. However, these results were obtained 
using only the EGRl consensus sequence to determine the stability of the WTIIDNA 
complex[l15, 1 161. Evidence suggests that WT1 (+KTS) recognizes unique motifs in gene 
promoters[83]. 
In addition to functioning as a transcription factor, WTl(+KTS) isoforms may have 
a unique function in post-transcriptional processing. Careful analysis of WTl localization 
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in WT1 expressing mouse kidney cell lines and tissue demonstrate that WTl(+KTS) co- 
localizes in nuclear "speckles" with splicing factors, a pattern which is disrupted by 
treatment with RNase A[121]. In the same study, WT1 co-immunoprecipitates with 
antigens common to small nuclear ribonucleoprotein particles (snRNPs) which are 
involved in mRNA splicing. More specifically, WTl(+KTS) is incorporated into 
spliceosomes and physically interacts with the ubiquitous splicing factor U2AF65, which 
is known to be present in nuclear speckles[100]. WTl also co-purifies with the poly(A)+ 
fraction of nuclear extracts from cell lines and fetal kidney tissue along with U2AF65 and 
p116, another splicing factor[ll4]. Three-dimensional structural modeling comparing 
WT1 with U1 A, a snRNP with known RNA recognition motif (RRM), identified a putative 
RRM in the N-terminal region of WTl, however a functional significance of this model 
has not been confirmed[lOO]. Recently, oligo(dT) chromatography to isolate RNPs 
followed by Western and SD gel analysis identified WT1 in RNPs in two human leukemia 
cell lines, for the first time suggesting that WTl may function in cancer by interacting with 
both DNA as a transcription factor, and RNA at the post-transcriptional leve1[163]. The 
mechanisms are currently unknown. To date, one RNA target of WT1 has been identified; 
gel mobility shift assays demonstrate that WTl binds to exon 2 of IGF-2 RNA in an 
interaction which requires the zinc finger region of WTl[24]. WT1 may therefore be one 
of a limited number of genes that affect gene expression at the DNA and RNA level. 
Regulation of WT1 
Transcriptional regulation 
Evidence suggests that the regulation of the WT1 gene is at the transcriptional 
level. During nephrogenesis, WTl mRNA and protein are expressed at the same time. In 
human cancers, there are rarely mutations in the wtl gene that could lead to its 
upregulation (Table 1). While many studies have focused on the role of WTl in 
tumorigenesis and organ development, relatively few have examined the regulation of the 
WTl gene. However, six transcription factors have been described that may be directly 
involved in WTl gene expression. PAX2, a transcription factor expressed at the same time 
as WT1 during nephrogenesis, binds to the WT1 promoter as shown by EMSA and DNaseI 
footprinting. Co-transfection of PAX2 caused upregulation of a WTl promoter reporter 
construct[l45]. Furthermore, in breast cancer and acute myeloid leukemia (AML), PAX2 
expression positively correlated with WT1 expression [222, 2201. Another paired box 
transcription factor, PAX8, both endogenous and exogenous, can regulate the WT1 
promoter as demonstrated by transient transfection experiments. Binding was 
demonstrated by EMSA[52]. GATA-1, a transcription factor involved in hematopoeisis, 
binds to an enhancer region in the WT1 gene and activates WT1 expression, shown by 
EMSA and co-transfection with enhancerlpromoter-CAT reporter constructs, 
respectively[263]. Furthermore, WT1 and GATA-1 mRNA are both expressed in 
hematopoeitic cell lines and mouse spleens. Microarray analysis of MDA-MB-468 cells 
transfected with a dominant negative Pea3 construct identified WTl as a potential target 
gene of the ETS transcription factor family member. Transfection with Pea3 increased 
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transcription of a reporter gene driven by the WTI promoter and increased WTI protein 
expression. Recombinant Pea3 is also able to bind to ETS binding sites in the WTI 
promoter as shown by EMSA[46]. Our laboratory has shown that several glioma cell lines 
express Pea3 (McCready et al., unpublished data). Deletion studies of the WTl promoter 
identified a putative Spl binding site as being involved in WT1 gene activation which was 
confirmed by stable transfection experiments, EMSA, and Southwestern analysis. In the 
same study, immunohistochemistry of the developing and adult rat kidney showed that Spl 
is expressed in structures that express WT1[31]. Interestingly, hypoxia inducible factor-1 
a (HIF-la) trans-activates the WTI promoter in cells exposed to hypoxia which leads to 
increased survival[250]. This is potentially interesting for brain tumor research, in that 
HIF-1 a expression and activity, particularly in response to intra-tumoral hypoxia, appear to 
play a prominent role in the biology of high-grade gliomas[94]. However, our laboratory 
has observed in vitro a decrease in WT1 mRNA expression in two WTI expressing 
glioblastoma cells in response to 24 hours of hypoxia (Appendix 1). 
Transient co-transfection studies in 293 transformed human fetal kidney cells show 
that WTl (+I+) strongly represses the WT1 promoter, while WTl (-I+) is the weakest 
repressor. WTI is one of the first genes to be shown to negatively autoregulate its own 
expression by direct interaction of the protein with its promoter, as demonstrated by 
EMSA[203]. Studies with 293 cells stably expressing an inducible WT1 (+I-) expression 
vector confirmed this result[138]. Hypermethylation of CpG islands is another mechanism 
of inhibiting the transcription of genes. The 5' promoter and intron 1 region as well as a 3' 
enhancer region of the wtl gene contain several sites of methylation, and are methylated in 
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several disease states including breast cancer and Wilms' tumor[l05, 123, 1401. In ovarian 
cancer, WT1 expression significantly correlates with methylation status[98]. Furthermore, 
in ovarian and breast cancer cells, treatment with a demethylating agent restores WT1 
expression[98, 123, 1281. However, the clinical relevance of WT1 gene methylation is 
questionable, as in breast cancer WTl is highly expressed regardless of methylation[l28]. 
In fact, in a large sample of human astrocytomas, WT1 was found to be hypermethylated, 
while other studies have found WT1 to be overexpressed in astrocytic tumors[267]. 
Post-transcriptional regulation 
Very little is known about the post-transcriptional regulation of WT1. WTl can be 
phosphorylated by protein kinase A and C (PKA, PKC) at Serine residues 365 and 393, 
which are located in the zinc finger 2 and 3 region of the protein[205, 2651. 
Phosphorylation of WT1 inhibits its ability to bind DNA and its ability to repress the 
PDGF-A promoter[205]. In addition, phosphorylation prevents WT1 binding to RNA and 
leads to cytoplasmic retention of the protein[265]. The significance of phosphorylation in 
human disease is unknown, however aberrant cytoplasmic localization of WT1 has been 
observed in cancer, including glioblastoma[l78]. 
WT1 and development 
Wilms' tumor arises from pluripotent embryonic precursor cells. The tumor is 
composed of the three cell types derived from these precursor cells which are normally 
present in kidney development; blastemal, stromal, and epithelial, and is therefore 
classically described as "triphasicm[154]. In addition, the observation that WTl mutations 
not only lead to Wilms' tumor development, but also to urogenital abnormalities supports a 
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critical role for wild-type WT1 in normal development. The study of WT1 dysregulation 
in Wilms' tumor has provided unique insight into the relationship between normal 
development and tumorigenesis. During development, WT1 is expressed in two types of 
tissues. One type is that undergoing mesenchymal to epithelial transition; the developing 
kidney, spleen, adrenal glands, the mesothelial lining of the peritoneal, pleural, and 
pericardial cavities, and the epithelial cells of the gonads[7, 191. The second is that of 
ectodermal origin, namely defined regions of the brain and spinal cord[7]. In the adult, 
WTl expression is restricted to the glomerular podocytes of the kidney and area postrema 
in the brain[2 1 71. 
Homozygous WTl mutant mice die early in gestation, possibly due to abnormal 
formation of the mesothelial lining of the heart, lung, and abdominal organs[l 10, 1601. 
Examination of the embryos revealed failure of kidney and gonad development which 
correlated with an increase in apoptotic cells in the tissue[llO]. Lack of spleen 
development in wtl-'- mice also demonstrated enhanced apoptosis in embryonic spleen 
cells[81]. This suggests that WT1 may function in early development as a survival factor. 
One potential mechanism for this effect could be by affecting the intrinsic apoptotic 
pathway via Bcl-2, which contains a WTE site in its promoter. WTl transactivates the 
anti-apoptotic gene encoding Bcl-2 which can protect cells against apoptosis-inducing 
stimuli[l44]. This may also be relevant to the function of WT1 in cancer, as the same 
study demonstrates that WTI levels correlate with Bcl-2 levels in a small sample of 
Wilms' tumors. Bcl-2 is overexpressed in 33 - 70% of glioblastoma however no studies to 
date have examined a correlation between WT1 and Bcl-2. 
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In addition to the pro-survival function, WT1 may mediate epithelial branching in 
the developing kidney. WTl trans-activates the amphiregulin gene, which encodes a 
ligand for EGFR that is expressed concurrently with WT1 in the developing kidney and 
that stimulates ureteric bud branching in mouse embryo kidney organ cultures[l24]. 
Amphiregulin expression has not been studied in glioblastoma, however it would be highly 
relevant, given the established importance of EGFR signaling in the tumorigenicity of 
glioblastoma. This is underscored by the observation that Amphiregulin is overexpressed 
in hepatocellular carcinoma and contributes to the increased growth rate and resistance to 
chemotherapy of these cancer cells[26]. 
Although the exact role of WTl in the development of the central nervous system 
has not been studied, several studies suggest a role for WTl in neuronal differentiation. 
Low levels of WT1 are expressed in the developing eye, specifically the retina[7,249]. 
WTl homozygous mutant mice have smaller eyes, thinner neuroretinas, and defective 
optic nerves, associated with decreased proliferation and increased apoptosis of retinal 
ganglion progenitor cells[249]. In vitro models of neuronal differentiation suggest 
potential mechanistic roles for WTl in this process. Retinoblastoma cells, which are 
malignantly transformed pluripotent retinal progenitor cells, can be induced to differentiate 
into neurons, during which WT1 is downregulated[25 11. Furthermore, inhibition of WT1 
expression in undifferentiated retinoblastoma cells partially blocks neuronal 
differentiation, suggesting that WTl plays an important role in the early stages of neuronal 
differentiation. Likewise, pheochromocytoma cells can be induced to differentiate into 
neurons by treating with nerve growth factor (NGF), which is known to downregulate 
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EGFR. This appears to be dependent on WT1 transcriptional regulation of the TCC 
repeat-containing EGFR promoter, as WT1 expression is decreased with NGF treatment 
and parallels the decrease in EGFR expression[l27]. The ability of WTl to up-regulate 
EGFR is interesting, given the central importance of EGFR signaling to glioblastoma 
behavior. In support of a role for WTl in neuronal differentiation, our laboratory has 
shown that WTl expression is downregulated in human NTera2 teratocarcinoma cells 
during retinoic acid-induced differentiation into neurons (Appendix B). 
WT1 and cancer 
Controversy exists surrounding the function of WT1 as a tumor suppressor or an 
oncogene in tumorigenesis[l5 11. The expression of WT1 in human cancer specimens has 
been extensively studied (Table 1-1). 
Table 1-1. Major studies examining WTl expression in cancer 
Cancer type Detection method Findings References 
Wilms' tumor PCR, PCR-SSCP 811 30 WTl  mutations 
Breast cancer RT-PCR, Western blot, 717 express WT1 mRNA, 27/31 
sequencing express WTl  protein, 0136 
mutations 
Leukemia Northern blot, RT- 1511220 acute leukemias and 
PCR, immuno- chronic leukemias in blast crisis 
,fluorescence express WTl  mRNA, 12/20 
express WTl  protein 
Pancreatic adeno IHC 30140 express WTl  protein 
Little et a/., 
199211 261, 
Varanasi et a/., 
199412461 
Loeb et a/. ,
2001 [ I  281, Oji et 
a/. , 200411 751 
Miwa et a/., 
1992[157], 
Menssen et a/., 
199511 531 
Oji et a/., 2004[177] 
Colorectal Real-time RT-PCR, 20128 express WT1 mRNA, 41/46 Oji et a/., 2003[179] 
adenoc IHC, sequencing express WT1 protein, 015 
mutations 
Thyroid cancer Real-time RT-PCR, 33/34 express WTl  mRNA, 20121 Oji et a/., 2003[176] 
IHC, sequencing express WT1 protein, 019 
mutations 
Boneandsoft Real-time RT-PCR, 28/36 express WTl  mRNA, 414 Ueda eta/., 
tissue sarcoma IHC, sequencing express WTl  protein, 018 2003[240] 
mutations 
Head and neck, Real-time RT-PCR, 42/56 express WTl  mRNA, 616 Oji et a/., 200311 731 
squamous IHC, sequencing express WTl  protein, 015 
mutations 
Lung cancer Real-time RT-PCR, 54/56 express WTl  mRNA, 516 Oji et a/., 200211 741 
IHC, sequencing express WTl  protein, 017 
mutations 
Ovarian cancer Northern blot, PCR- 15/20 express WTl  mRNA, 0120 Bruening etal., 
SSCP mutations 199311 61 
Esophageal Real-time RT-PCR, 12/12 express WT1 mRNA, 36/38 Oji et a/., 2004[180] 
cancer IHC express WTl  protein 
Malignant PCR-SSCP, IHC No mutations, 54/56 express Kumar-Singh et a/., 
mesothelioma WTl  protein, 1/33 WTl  mutation 199711 1 I ] ,  Park et 
a/. , 199311 831 
Desmoplastic RT-PCR, sequencing 416 rearrangement with fusion of Gerald et a/., 
small round cell EWS and WT1 genes 19951571 
tumor 
Retinoblastoma RT-PCR, IHC 616 express WT1 mRNA and Wagner et a/., 
protein 2002[251] 
Malignant glioma RT-PCR, real-time RT- 35146 express WTl  mRNA, 71/76 Menssen et a/., 
PCR, IHC express WTl  protein 2000[152], Dennis 
etal., 2002[43], Oji 
et a/., 200411 781, 
Nakahara et a/., 
200411 681 
Abbrev., RT-PCR, reverse-transcriptase polymerase chain reaction; SSCP, single strand 
comformational polymorphism; IHC, immunohistochemistry 
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Although originally discovered as mutated in Wilms' tumor and classified as a tumor 
suppressor, WTI mutations are relatively rare, occurring in a small percentage of Wilms' 
tumors, leukemia, mesothelioma, and the rare desmoplastic small round cell tumor[126, 
102, 1831. In contrast, wild-type WTl is overexpressed in breast cancer, acute leukemia, 
colorectal cancer, lung cancer, ovarian cancer, head and neck squamous cell carcinoma, 
and bone and soft tissue sarcomas[l28, 157, 179, 174, 16, 173,2401. As shown in Chapter 
2 below, we have confirmed that overexpression of wild-type WT1 is present in 
approximately 80% of glioblastomas, as well as 80% of grade 11 and I11 gliomas[30]. 
Multiple studies have examined the role of WT1 in leukemia. Wild-type WTI is 
overexpressed in the majority of acute leukemia relative to normal bone marrow and 
peripheral blood cells, indicating that WT1 is a reliable leukemia marker[l57, 153, 881. 
WTI is also expressed in chronic leukemia in blast crisis, but is absent in chronic leukemia 
in the chronic phase[] 57, 1.531. WTl is mutated in approximately 10-1 5% of leukemia, 
primarily acute myelogenous leukemia[l02]. High WTI expression correlates with worse 
prognosis in acute leukemia and can be used to predict the progression of myelodysplastic 
syndrome to acute leukemia[90,23 I]. Furthermore, WTl levels in bone marrow and 
peripheral blood after treatment are useful in the detection of minimal residual disease and 
can help tailor additional therapies[90, 891. Clues to the function of WTI in leukemia 
come from overexpression and inhibition studies. Transient transfection of wild-type WTI 
into normal myeloid progenitor cells inhibits the differentiation of the cells, which is 
significant in that differentiation arrest is characteristic of leukemia[91]. Overexpression 
of WTI in a variety of human leukemia cell lines similarly causes a block in 
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differentiation, thereby providing a potential role for WTl in leukemogenesis[229, 44,251. 
The capacity of WTl to block differentiation is potentially clinically relevant, as high WT1 
expression correlates with less differentiated samples in a large group of human 
AML[185]. WTl expression can also protect leukemia cells from chemotherapeutic agents 
by decreasing activity of the intrinsic apoptotic pathway which is associated with an 
increase in anti-apoptotic Bak expression[93]. Simpson et al., provide further evidence for 
a protective role of WTl in leukemia cell behavior by demonstrating that the anti-apoptotic 
Bcl-2 family member A 1 IBFL 1 is directly trans-activated by WT1[225]. When leukemia 
cells expressing endogenous WTl are induced to differentiate, WTl is down-regulated 
which is associated with a decrease in c-myc expression[215]. From a therapeutic 
standpoint, WT1 downregulation by antisense oligonucleotides causes a decrease in 
proliferation of leukemia cells which is accompanied by a decrease in viability and an 
increase in apoptosis[3]. Additional studies show that apoptosis induced by WTl silencing 
is associated with an increase in pro-apoptotic Bax expression[93]. WTl antisense 
oligonucleotide treatment does not effect the viability of normal cells, suggesting the 
potential for WTl as an attractive target for therapy[264]. 
Wild-type WT1 is overexpressed in the majority of breast cancer specimens 
relative to normal breast tissue[l28]. WT1 protein is highly expressed in estrogen receptor 
negative tumors which are more aggressive[223]. In a large clinical sample, real-time RT- 
PCR analysis revealed that WT1 mRNA level is a significant prognostic factor as high 
WT1 expression correlated with a significantly lower 5 year disease free survival[l59]. 
WT1 overexpression may be in part due to the RTK HER21neu which is overexpressed in 
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aggressive breast cancers, as overexpression of HER21neu in breast cancer cells causes 
upregulation of WTl expression and HER2Ineu inhibition decreases WTl 
expression[239]. The same study also indicates the involvement of AKT which is 
activated by HER2Ineu. WTl expression increases in breast cancer cells when treated with 
growth stimulatory agents and, more importantly, antisense oligonucleotide-induced WTl 
downregulation inhibits proliferation by inducing G1 arrest[239, 2701. The decrease in 
proliferation is associated with decreased expression of cyclin Dl ,  but the exact 
mechanism is not known. All four WTl isoforms also trans-activate the c-myc proto- 
oncogene in breast cancer cells by directly stimulating the c-myc promoter[76]. Activation 
of c-myc is known to stimulate proliferation, and therefore may provide an explanation for 
the decrease in cancer cell proliferation after WTl downregulation. However proliferation 
was not determined after WTl induced c-myc upregulation[76]. Nevertheless, this may be 
relevant to glioblastoma biology as c-myc is overexpressed in tissue samples[236]. 
Decreased WTl expression also induces apoptosis in breast cancer cells which parallels a 
decrease in the anti-apoptotic WTl target gene, Bcl-2[239]. The observation that WT1 
represses the insulin-like growth factor-1 receptor (IGF-1 R), which acts as a survival factor 
in cancer, adds complexity to the putative oncogenic function of WTl [I 971. The 
mechanism involves WT1 interaction with the estrogen receptor. High levels of WT1 
expression in breast cancer are associated with estrogen receptor negative tumors[223], so 
the physiologic relevance of this observation is not known. Nevertheless, the exact role of 
WTl in human cancer is exceedingly complex and to date not fully understood. 
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WTl and invasion 
The relationship between WTl and cell invasion has not been extensively studied. 
A recent study, however, suggests that WTl may play a role in migration and invasion[95]. 
WTl overexpression in TYK ovarian cancer cells caused the cells to adopt a smaller size 
and "fibroblast-like" morphology which was associated with decreased expression of a- 
actinin 1 and cofilin, two cytoskeletal proteins. The expression of gelsolin, which is 
involved in actin filament assembly, is upregulated in response to WT1 expression. WTl 
overexpression also decreased focal adhesions, while increasing migration and invasion. 
The phenotype could be reverted by forced expression of a-actinin 1 and cofilin, or 
gelsolin silencing, suggesting that WTl may affect invasion by modulating cytoskeletal 
structures. As described above, a-actinin 1 plays an important role in glioma invasion by 
linking integrins to the actin cytoskeleton. Furthermore, the change in cell morphology 
induced by WTl expression is similar to that adopted by the invading glioma cell. 
Morphologically, glioma cells prone to invasion are small anaplastic cells[96, 601. In a 
separate study, WTl was found to regulate the E-cadherin promoter, a cell adhesion 
molecule involved in cancer cell invasion[85]. Given the characteristic invasiveness of 
glioblastoma, the study of WTl and glioma cell invasion is warranted. 
WTI andp53 
As the debate rages over the function of WT1 as a tumor suppressor or oncogene, a 
player of particular interest to glioma biology has arisen as a potential explanation: the 
p53 tumor suppressor. In osteosarcoma cells and immortalized kidney cells, WTl and p53 
co-immunoprecipitate demonstrating direct binding[l37]. Arguing for an oncogenic 
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function of WT1, WTl inhibits p53 mediated apoptosis in addition to stabilizing the p53 
protein[l36]. In large samples of female genital tract tumors and a small sample of Wilms' 
tumors, WT1 expression strongly correlates with p53 expression[2, 1361. In endometrial 
carcinoma, WT1 and p53 double positivity is associated with worse prognosis[47]. 
Unfortunately, none of these studies screened the p53 gene for mutations, which is crucial 
for interpretation because of the stabilizing effect of WTl on p53. However, our 
laboratory has shown that in a large sample of glioblastoma specimens, WTl expression 
correlates with wild-type p53 (please see Chapter 2 and refl301). This may explain, in part, 
the observation that 30% of glioblastomas overexpress p53 in the absence of stabilizing 
mutations[202]. Furthermore, it may provide a partial mechanism for functional 
inactivation of wild-type p53 in glioblastoma. It would be interesting to determine if WTl 
expression and MDM2 amplification are mutually exclusive in glioblastoma, which would 
suggest two pathways of functionally inactivating p53, however this study has yet to be 
undertaken. 
The reciprocal effect of the WTlIp53 interaction is exemplified by the dual 
regulation of the insulin-like growth factor-I receptor (IGF-IR) promoter. The IGF-IR is 
overexpressed in cancer and may function in malignant transformation by inhibiting 
apoptosis[54]. WTl represses the IGF-IR promoter due to multiple WTl binding sites in 
embryonic kidney cells and prostate cancer cells[261, 371. The decrease in IGF-IR 
expression leads to decreased proliferation. Wild-type p53 also represses transcription of 
the IGF-IR however this is not a consequence of direct binding to the promoter[260]. As 
another consequence of their physical interaction discussed above, p53 inhibits the 
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transcriptional repression activity of WTI at the IGF-IR[87]. This mechanism may be 
more generalizable as reciprocal effects on transcriptional regulation due to WTlIp53 
interaction have been documented in other studies[l37, 1361. An interesting side note is 
that p53 increased the expression of WT1, a finding which requires follow-up[87]. It is 
possible that one component of the tumor suppressive function of p53 is to act as a switch 
which converts WTl to a repressor of oncogenes involved in transformation, such as the 
IGF-IR. Potentially, in certain contexts, such as wild-type p53, WTI acts as a tumor 
suppressor, while in others, such as the absence of p53, WT1 acts as an oncogene. 
Conclusion 
As a gene involved in the development and differentiation of the central nervous 
system, in addition to its function as a regulator of several key glioma associated 
molecules, WTI is in a unique position to be involved in both normal development and 
gliomagenesis, when aberrantly re-activated. The ability of WT1 to modulate receptor 
tyrosine kinase pathways, anti-apoptotic proteins, components of cell cycle regulation, cell 
invasion, and the tumor suppressor p53 are of particular interest to glioma biology. More 
extensive studies of the function of WTI in glioblastoma may prove WT1 to be critical to 
gliomagenesis. Furthermore, WT1 targeting strategies may decrease the tumorigenicity of 
glioma cells and potentially enhance other anti-glioma therapies, proving it to be a gene of 
substantial clinical significance in neuro-oncology. 
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Abstract 
Object. Wilms' tumor 1 (WTl) is overexpressed in many types of human cancer. 
Studies demonstrate that WTl promotes tumor cell proliferation and survival in some cell 
lines by inhibiting p53-mediated apoptosis, however this relationship has not been studied 
in gliomas. 
Methods. We screened nine malignant glioma cell lines, fifty glioblastoma (GBM) 
samples and sixteen lower grade glial tumors for WT1 expression. 519 cell lines, 44/50 
GBM samples and 13/16 lower grade gliomas expressed WT1 mRNA by reverse 
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transcriptase polymerase chain reaction (RT-PCR) analysis. WT1 expression was not 
detected in normal astrocytes. Two WT1 isoforms, +/+ and -/+, were expressed by the 
majority of these samples. Real-time PCR analysis of the GBM cell lines revealed that the 
level of WT I mRNA ranged from 6.33 - 2 14.70 ng per ng 1 8s RNA. We screened the 
GBM samples for p53 mutation by PCR and single-stranded conformational 
polymorphism (PCR-SSCP) analysis and demonstrated an association between WTI 
expression and p53 status. Tumors that contained wild-type p53 were significantly more 
likely to express WTl than tumors that contained mutant p53. 
Conclusions. The presence of WT1 in glioma cell lines and the majority of primary 
tumor samples, and its absence in normal astrocytes, suggests that WTl expression is 
important in glioma biology. 
Introduction 
Glioblastoma multiforme (GBM) is a WHO grade IV glial tumor that carries a 
universally poor prognosis. Extremely resistant to both radiotherapy and chemotherapy, 
the median survival is only one year. Unfortunately, it is also the most common primary 
brain tumor[27]. Decades of intense research have determined that alterations in several 
growth factors such as PDGF, EGF and their receptors, and tumor suppressors such as p53, 
Rb, and PTEN are important to glioma biology[l34]. Despite these advances, a significant 
clinical improvement has not been realized. Therefore, a more complete characterization 
of the molecular changes in gliomagenesis is necessary to uncover potential markers and 
targets for novel therapies. Previous studies examined the expression of the Wilms' tumor 
1 (WT1) gene in human brain tumors, including gliomas, and found detectable expression 
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in tumor cells, while normal cells expressed none[43, 152, 168, 1781. To date, no studies 
have examined the WTl isoforms expressed by these tumors or the contribution of WTI to 
prognosis and other clinicopathologic characteristics. 
WTI was originally discovered as mutated in nephroblastoma, a common pediatric 
kidney cancer also known as Wilms' tumor[23]. It was subsequently found that the wtl 
gene, located at chromosome locus 11~13 ,  encodes a 52-55 kD polypeptide containing 
four C-terminal zinc fingers and an N-terminal transactivation domain[75]. The structure 
is consistent with its known function as a transcription factor, and a large number of target 
genes have been identified[l5 11. Furthermore, the message is alternatively spliced to 
generate four main isoforms, designated +I+, -I+, +I-, -I-, depending on the inclusion or 
exclusion of exon 5 and nine nucleotides in exon 9 known as KTS, respectively, which 
may modulate the transcriptional activity of the protein[75]. WTl plays a major role in 
normal development, most notably in the urogenital system, and is expressed in the 
developing central nervous system[77,7]. 
Although originally classified as a tumor suppressor, WTl does not adhere to the 
norn~al characteristics of such a gene. It is not ubiquitously expressed throughout the adult 
body, nor is it commonly mutated in cancers[l9]. On the contrary, it is overexpressed in 
many types of cancer, including breast carcinoma and acute leukemia. In both cases, high 
levels of WTI expression detected by real-time PCR correlate with a worse prognosis 
relative to those that express low levels of WTI [159, 901. Furthermore, inhibition of WTI 
expression in human breast cancer and leukemia cell lines using antisense modalities leads 
to differentiation, decreased proliferation, and increased sensitivity to treatment[270,229]. 
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Inactivation of the tumor suppressor p53 is a common aberration in human 
malignant gliomas. p53 has well established functions in cell-cycle arrest and apoptosis 
induced by DNA damage, as well as in DNA repair, senescence, and differentiation[248]. 
The p.53 gene is mutated in approximately 30% of GBM with the vast majority of these 
mutations being point mutations located in exons 5-8[12]. Many treatments for glioma, 
such as radio- and chemotherapy, cause DNA damage, and thus are likely to rely on p53 
function for a therapeutic response[l33]. Alterations in other genes, such as mdm2, which 
targets p53 for degradation, represent alternative means of inactivating p53 in 
gliomas[l96]. In some cell types, WT1 inhibits p53-mediated apoptosis[l36]. 
In this study, we assessed a large sample of human glioma cell lines and glioma 
specimens for WT1 isoform expression and p53 status, to determine if a correlation exists 
between WT1 expression and prognosis, or p53 status. The majority of glioma cell lines 
and specimens expressed the +KTS isoforms of WTl which correlated with the presence 
of wild-type p53. These results suggest a critical role for WTl+KTS isoforms in glioma 
biology, possibly through interaction with the tumor suppressor p53. 
Clinical Materials and Methods 
Cell culture and tissue preparation 
Human glioma cell lines (U87-MG, T98G, U373, U118, LN18, LN229) were 
obtained from American Type Culture Collection and were grown and passaged in 
Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, glutamine, non- 
essential amino acids, and 1% penicillin-streptomycin in a humidified atmosphere of 5% 
COz. LN-Z308 glioma cells, a kind gift from Dr. Erwin Van Meir, were maintained in the 
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same conditions. VC95G and VC95T were derived in our laboratory from human 
glioblastoma tissue and were maintained in the same conditions. Normal human astrocytes 
(NHA) were obtained commercially from Clonetics (Cambrex Biosciences). PC3 prostate 
carcinoma cells were used as a positive control for WT1 expression. For RNA extraction, 
the cell lines were plated at a concentration of 1 X 1 o6 cells11 00 mm tissue culture dish and 
allowed to attach overnight. Fresh frozen glioma specimens were selected from the VCU 
Neuro-Oncology Tissue and Cell Culture Facility. The specimens were obtained in the 
operating room, dissected from adventitial material, immediately snap frozen in liquid 
nitrogen, and stored at -80" C in accordance with a protocol approved by the VCU 
Institutional Review Board. Before RNA, DNA, or protein extraction, tissue was 
homogenized using a -80" C mortar and pestle. Total RNA was isolated from tissue and 
cell line samples using the Trizol extraction protocol (Invitrogen). DNA was isolated from 
tissue using the QIAamp DNA Mini kit protocol (Qiagen). The concentration of RNA and 
DNA was determined by spectrophotometry. Protein was extracted from cell lines using 
SDS buffer (50 mM Tris-Cl, 1% SDS, 10% glycerol) supplemented with protease 
inhibitors. Protein was extracted from tissue samples using the same extraction buffer 
followed by sonication. The concentration of protein was determined by DC protein assay 
(BioRad). 
RT-PCR and sequencing 
Reverse transcription was performed using the Superscript I1 RT-PCR system 
(Invitrogen). A 10 pl sample of the RT reaction mixture was added to 40 p1 PCR mixture 
containing PCR buffer, dNTP mixture, Platinum Taq DNA polymerase, primers, and 
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MgC12 to a final concentration of 1.82 mM. The first set of amplifications utilized a 2 1 - 
mer 5'-GTT-ACA-GCA-CGG-TCA-CCT-TCG-3' located in exon 2 and a 22-mer 5'- 
CCT-GAA-TGC-CTC-TGA-AGA-CAC-C-3' located in exon 6 (primer pair 1, Figure 2- 
la). A separate set of amplifications was performed with a 22-mer 5'-GAC-GTG-TGC- 
CTG-GAG-TAG-CCC-C-3', a primer located in exon 7 and a 21 -mer 5'-GCT-GCC-TGG- 
GAC-ACT-GAA-CGG-3'' a primer located 17 bp upstream of the stop codon (primer pair 
2, Figure 2-la). In a separate reaction, 2 p1 of RT reaction mixture was added to 48 p1 of a 
similar PCR mixture to amplify a segment of GAPDH mRNA as a control. PCR products 
were electrophoresed on ethidium bromide-stained 1 % agarose gels. For sequencing, the 
PCR product was extracted from gels using the QIAquick Gel Extraction Kit (Qiagen). 
The extract was then sent to the Molecular Core of the Virginia Commonwealth 
University-Massey Cancer Center Nucleic Acids Research Facilities for direct sequencing 
to determine the KTS status of the mRNA. 
Real-time PCR analysis 
The experiments were performed in the ABI Prism@ 7900 Sequence Detection 
System (Applied Biosystems) using the TaqMan@ One Step PCR Master Mix Reagents 
Kit (P/N: 4309169). All the samples were tested in triplicate under the conditions 
recommended by the fabricant. The cycling conditions were: 48OC/30min; 95°C/10min; 
and 40 cycles of 95"C/15sec and 60°C/lmin. The cycle threshold was determined to 
provide the optimal standard curve values (0.98 to 1.0). The probes and primers were 
designed using the software Primer Express@ 2.0. The probes were labeled at the 5' end 
with FAM (6-carboxyfluorescein) and at the 3' end with TAMRA (6- 
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carboxytetramethylrhodamine). Ribosomal RNA (1 8 s  rRNA) from the Pre-developed 
TaqManBAssay Reagents (PIN: 43 10893E) was used as endogenous control. The 
reactions and the synthesis of the probes and primers were performed in the VCU Nucleic 
Acid Research Facilities. 
Western blot analysis 
For WTl protein analysis, 100 pg of total protein lysate was separated by SDS- 
PAGE, transferred to nitrocellulose membrane, and the membrane blocked with 5% nonfat 
milk solution for 1 hour at room temperature. Mouse anti-WT1 monoclonal antibody 
(Dako) was diluted 1 :200 in blocking buffer. The membranes were incubated with 
primary antibodies overnight at 4°C. The membranes were washed six times in Tris 
buffered saline containing 0.05% Tween-20 before and after a one hour incubation at room 
temperature with horseradish peroxidase-conjugated anti-mouse secondary antibody 
(Rockland, Inc.) at a dilution of 1 : 1000. Blots were developed using the ECL detection 
System (Amersham Biosciences). Anti-Cyclophilin A monoclonal antibody (Upstate 
Biotechnology) at a dilution of 1 : 1000 was used as a control for protein loading. 
PCR-Single strand conformational polymorphism analysis 
100 ng of genomic DNA was used as the template for PCR as described above. 
Exons 5-8 of the human p53 gene were amplified from tumor DNA in 4 separate reactions 
using primer pairs described previously[l88]. DNA extracted from blood samples 
obtained from five normal controls was used as SSCP controls. The PCR products were 
electrophoresed on a 7% acrylamide gel and visualized by silver staining. Bands which 
differed from those in normal control blood were considered mutations. 
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Statistical Analysis 
WT1 expression was dichotomized as tumors expressing full-length WT1 versus 
non-full-length, which included tumors not expressing WTl and those expressing 
potentially truncated WT1. Similarly, p53 was dichotomized as wild-type versus mutant. 
Thereafter, the relationship between WT1 and the categorical clinical variables (e.g., sex, 
tumor location, and p53 status) of the GBM patients was first analyzed using Fisher's exact 
test. For any variable found univariately to be significantly associated with WTl, a 
logistic regression model was fit to estimate the odds ratio and associated 95% confidence 
interval. The relationship between WT1 expression and the continuous variable age was 
analyzed using a t-test. Survival was calculated from the date of diagnosis of GBM until 
the date of death, censoring for patients still alive. Kaplan-Meier survival curves were 
estimated for the WT1 full-length and non-full-length groups and were compared using the 
log-rank test. 
Results 
Malignant glioma cell lines expressed WT1. We screened nine human malignant 
glioma cell lines for WT1 expression by RT-PCR, first using primer pair 1 that spans the 
exon 5 splice site (Figure 2-lb). Five glioma cell lines expressed detectable WT1 mRNA. 
RT-PCR using primer pair 2 spanning the KTS splice site in exon 9 confirmed WT1 
mRNA expression in the five cell lines and a lack of expression in normal human 
astrocytes (Figure 2-lc). Sequencing of the PCR products revealed that the cell lines 
expressed the +I+ and -I+ isoforms of WT1, with the exception of VC95G, which 
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expressed the +/- and -1- isoforms. We quantified the level of WTl mRNA, relative to 18s 
RNA, being expressed by the cell lines using real-time PCR (Figure 2-ld). 
Figure 2-1. Human glioma cell lines express WT1 mRNA. A. Schematic 
representation of the WT1 cDNA. Each exon is depicted as a separate numbered box. 
Alternative splices are depicted as darkly shaded boxes. Primers and products are depicted 
as arrows. Primer pair 1 spans the splice site in exon 5. The alternative splice in exon 9 is 
designated KTS and is spanned by primer pair 2. B. Glioma cell line RNA extract was 
analyzed by RT-PCR using primer pair 1. Numbered lanes correspond to the following 
cell lines; (1) PC3 prostate carcinoma positive control, (2) NHA normal human astrocytes, 
(3) U87MG, (4) VC95G, (5) VC95T, (6) T98G, (7) U373, (8) U118, (9) LN18, (lo) 
LN229, (1 1) LN-Z308, (12) no RNA template control, (13) no cDNA template control. In 
a separate reaction, detection of GAPDH was included as a control for RNA loading. C. 
Glioma cell line RNA extract was analyzed by RT-PCR using primer pair 2. D. Levels of 
WTl mRNA expression were determined by real-time PCR. WTl levels are shown as 
ratios of ng WT1: ngl8S mRNA levels. 
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The real-time PCR confirmed the qualitative RT-PCR data, detecting WT1 mRNA in the 
same lines by both assays. LN18 and T98G cell lines expressed relatively high levels of 
WT1 mRNA, while VC95G, U118, and U373 expressed low levels. Sequencing and real- 
time PCR data are summarized in Table 2- 1 
Table 2-1. Sequencing data demonstrating the specific isoforms and levels of 
VVTl mRNA expressed by glioma cell lines per ng 18s RNA 
Cell line WT1 isoform* ng WT1 I ng 18s 
LN229 Nd 0.0 k 0.0 
LN-Z308 Nd 0.0 & 0.0 
*VVTl isoforms are designated (exon 5)/(KTS) or nd, not 
detected 
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To confirm WTl gene expression at the protein level, we performed western blotting on a 
representative subset of the cell lines; U87-MG, T98G, LN18, and LN-Z308. Consistent 
with the RT-PCR data, T98G and LN18 cells expressed WTl protein, while U87-MG and 
LN-Z308 cells did not (Figure 2-2). 
Figure 2-2. Western blot analysis of WT1 protein expression. 100 pg of protein 
extracted from PC3 prostate carcinoma positive control, U87MG, T98G, LN-18, and LN- 
2308 cell lines were analyzed by Western blotting using mouse anti-WT1 monoclonal 
antibody (Dako). Blots were also probed with anti-cyclophilin A to demonstrate equal 
protein loading. CypA, cyclophilin A. 
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Glioblastoma multiforme specimens expressed WT1. Previous studies of small 
samples of GBM tissue suggest that WTl expression is not clinically relevant and is only a 
phenomenon caused by extended culture of glioma cells[43, 1521. We found that WTI 
mRNA expression did not change with increasing passage number in established glioma 
cell lines (data not shown). To confirm that a significant proportion of human malignant 
gliomas expressed WTl, we screened fifty GBM specimens. The specimens contained > 
80% tumor tissue relative to normal brain tissue as determined by pathologic analysis. 
Twenty three (46%) of the samples were from female patients and the remaining twenty 
seven (54%) were from male patients. The average age of the patients was 57.3 years. 
Nine (1 8%) of the GBM samples were located in the frontal lobe, 11 (22%) in the parietal 
lobe, 20 (40%) in the temporal lobe, 9 (1 8%) in the occipital lobe, and one (2%) in the 
insular lobe. The patient population survived a median of 45 weeks after the diagnosis of 
GBM. By RT-PCR, 44/50 (88%) of the specimens expressed WTl mRNA (Table 2-2). 
Table 2-2. Summary table depicting the Wl expression and p53 mutaion status 
of glioblastoma multiforme specimens and respective clinical information. 
Pt # Sex Age Location WTl(exon 5) WTl(KTS) P53 Survival (w) 
1 F 39 Frontal nd nd wild-type living 
2 F 79 Occipital +,-exon 5 +KTS wild-type 33 
3 M 80 Temporal +,-exon5 + KTS wild-type 11 
4 M 68 Occipital +,-exon 5 nd wild-type 19 
5 M 75 Temporal +,exon 5 + KTS wild-type 15 
6 F 66 Occipital +,-exon 5 +KTS wild-type 48 
7 M 19 Frontal +,-exon5 nd mutant 64 
8 M 45 Occipital +,-exon 5 nd mutant 19 
9 F 55 lnsula +,exon 5 +KTS wild-type 39 
10 F 60 Parietal nd nd mutant 82 
11 F 49 Parietal +,-exon 5 +KTS mutant 67 
12 F 58 Parietal +,-exon 5 +KTS wlld-type 36 
13 M 64 Occipital +,-exon 5 +KTS wild-type 184 
14 M 49 Temporal nd nd wild-type 77 
15 F 77 Parietal +,exon 5 + KTS wild-type 14 
16 F 43 Temporal +,exon 5 + KTS wild-type 106 
17 M 61 Temporal +,exon 5 +KTS wild-type 124 
18 M 64 Frontal +,exon 5 +KTS wild-type 27 
19 M 62 Frontal +,exon 5 +KTS wild-type 39 
20 F 60 Temporal +,-exon 5 +KTS wild-type 4 
21 F 51 Occipital +,-exon 5 +KTS wild-type 190 
22 F 20 Temporal +,-exon 5 + KTS wild-type 107 
23 F 54 Temporal +,exon 5 + KTS wild-type 49 
24 F 67 Occipital +,-exon 5 +KTS mutant 84 
25 M 54 Temporal +,-exon 5 +KTS wild-type 67 
26 M 33 Frontal +,-exon 5 +KTS wild-type 55 
27 M 60 Temporal +,-exon 5 nd mutant 28 
28 F 47 Parietal +,-exon 5 +KTS wild-type 66 
29 M 64 Parietal +,-exon 5 +KTS wild-type 14 
30 F 44 Frontal +,-exon 5 +KTS wild-type 48 
31 F 58 Parietal +,-exon 5 +KTS mutant 61 
32 M 51 Parietal +,-exon 5 +KTS wild-type 44 
33 M 65 Occipital +,-exon 5 +KTS mutant ltflu 
34 M 78 Parietal +,-exon 5 +KTS wild-type 8 
35 M 80 Temporal +,exon 5 + KTS wild-type 29 
36 F 64 Temporal +,exon 5 + KTS wild-type 88 
37 F 68 Frontal nd nd mutant 15 
38 M 76 Parietal nd nd wild-type 5 
39 F 51 Frontal +,-exon 5 +KTS mutant 20 
40 M 37 Temporal +,-exon 5 +KTS wild-type 10 
41 F 49 Occipital +,-exon 5 +KTS wild-type 102 
42 F 33 Parietal +,exon 5 +KTS wild-type 45 
43 M 74 Temporal nd nd wild-type 52 
44 M 63 Temporal +,-exon 5 +KTS mutant 45 
45 M 72 Temporal +,exon 5 +KTS wild-type 25 
46 M 50 Frontal +,exon 5 + KTS wild-type 13 
47 M 62 Temporal +,exon 5 +KTS wild-type 77 
48 M 37 Temporal +,-exon 5 +KTS mutant 29 
49 F 59 Temporal +,exon 5 +KTS wild-type 85 
50 M 71 Temporal +,exon 5 +KTS wild-type 63 
Pt #, patient number, nd, not detected, Itflu, lost to follow-up, -,+exon 5 
denotes presence of both - and +exon 5 isoforms. 
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Forty samples expressed WTl detectable by both primer pairs. Similar to the cell line 
isoform profile, all 40 expressed both the +/+ and -/+ isoforms of WT1. However, samples 
# 4, 7, 8, and 27 expressed WT1 detectable only by primer pair 1. There was no 
significant correlation between WTl expression and either sex (p = 0.31), age (p = 0.72), 
or location (p = 0.81). Patients with tumors that expressed WTI survived for a shorter 
time than those that did not express WT1 (45 weeks versus 52 weeks) but that trend did not 
approach statistical significance (p = 0.87). To confirm that the samples that expressed 
WTl mRNA expressed WTl protein, western blot analysis was performed on samples # 
13, 18,2 1,28, 3 1, and 39, all of which expressed WTl mRNA. All of the samples tested 
expressed detectable WT1 protein (data not shown). 
WT1 expression was associated with p53 status. As WTl interacts with p53 and 
in certain types of cancer correlates with p53 expression, we screened .the GBM samples 
for p53 status[l37, 2,471. Using PCR-SSCP, we screened all 50 GBM samples for p53 
mutations in exons 5-8 (Figure 2-3). 
Figure 2-3. Representative SSCP analysis of exon 5 ofp53 gene. Normal control lanes 
contain DNA extracted from 5 different patients without brain tumors. Lanes 1-9 contain 
DNA extracted from GBM samples from patients 1-9. Mutations in samples 7 and 8 are 
demonstrated as extra fractions compared to normal controls and are indicated by arrows. 
normal control 
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We detected mutations in 12 samples (Table 2-2). The expression of wild-type p53 was 
significantly associated with WT1 expression (p < 0.05, Table 2-3). 
Table 2-3. WTl expression is associated with p53 mutation status as determined 
by PCR-SSCP in human GBM specimens 
WT1 
Full-length Non full-length* Total 
~ 5 3  Mutant 7 5 12 
Total 40 10 50 
*Non-full length includes putative truncated mutant WTl and lack of WT1 
expression. 
**Tumors with wild-type p53 are significantly more likely to express full- 
length WTl than those with mutant p53 (odds ratio 4.714; 95% CI 1.069, 
20.789) 
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Logistic regression showed that tumors with wild-type p53 were significantly more likely 
to express full-length WTl than those with mutant p53 (odds ratio 4.714; 95% confidence 
interval 1.069,20.789). 
Lower grade glial tumors expressed WT1. To assess the WTl expression 
pattern in relation to glioma progression, we screened sixteen lower grade gliomas for 
expression of WT1. 415 pilocytic astrocytomas, 111 low grade glioma, 414 
oligodendrogliomas, 214 anaplastic astrocytomas, and 212 anaplastic oligodendrogliomas 
expressed WT1 by RT-PCR analysis (Table 2-4). 
Table 2-4. Summary table depicting the Wl expression status of 
lower grade glioma specimens 
Pt # Dx Sex Age W l ( e x o n  5) W l ( K T S )  
5 1 PA M 6 +,-exon 5 +KTS 
52 PA F 12 +,-exon 5 +KTS 
5 3 PA F 6 +exon 5 - KTS 
54 PA F 11 nd n d 
55 PA F 1 +,-exon 5 +KTS 
56 All M 5 +exon 5 +KTS 
57 011 M 35 +,-exon5 +KTS 
58 011 M 31 +,-exon 5 +KTS 
59 011 F 29 +,-exon5 +KTS 
60 011 M 47 +,-exon 5 +KTS 
6 1 AAIII M 63 +,-exon 5 +KTS 
62 AAllI F 13 nd n d 
63 AAllI F 52 nd n d 
64 AAIII M 47 +,-exon 5 +KTS 
65 AOlll M 50 +,-exon5 +KTS 
66 AOlll M 36 +,-exon5 +KTS 
Pt#, patient number, Dx, diagnosis, PA, pilocytic 
astrocytoma, All, a s t r ~ c y t o ~ a ,  011, oligodendroglioma, 
AAIII, anaplastic astrocytoma, AOlll, anaplastic 
astrocytoma, nd, not detected, -,+exon 5 denotes 
presence of both - and + exon 5 isoforms 
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With the exception of one pilocytic astrocytoma (#53) which expressed the +I- isoform and 
one low grade glioma which expressed the +I+ isoform only, all low grade tumors 
analyzed expressed both +I+ and -I+ isoforms of WT1. 
Discussion 
Of the nine human malignant glioma cell lines and the large sample of human 
GBM specimens we characterized, we demonstrated that the majority expressed WT1. All 
of the tumor samples that expressed the +KTS isoforms, which are the most prevalent in 
nature[75]. Four out of five cell lines that expressed WTI expressed the (+KTS) isoforms. 
One cell line, VC95G, expressed only the (-KTS) isoforms of WTl, raising the possibility 
of a change due to growth conditions in culture. Nevertheless, the fact that the isoforms 
expressed by the majority of our glioma cell lines mirror those expressed in human 
glioblastoma provides the potential for in vitro studies to examine the function of WTl in 
this disease process. We also screened 16 lower grade glial tumors for WTI mRNA 
expression of which 13 expressed WTl . Since a subset of GBM, the secondary GBM, is 
thought to arise from preexisting lower grade gliomas[258], this finding suggests that 
aberrant expression of WTl may be an early change in human gliomagenesis. This is 
further supported by the observation that, with the exception of one pilocytic astrocytoma 
specimen, the isoform expression profile of the lower grade gliomas mirrored that of 
GBM. Normal astrocytes did not express WT1, a finding which was to be expected as 
WTl, although expressed in restricted areas of the developing CNS, is not expressed in the 
adult brain[7]. 
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WTl binds to the tumor suppressor p53, which inhibits p53-mediated 
apoptosis[l36, 1371. More recent studies of WTlIp53 interactions reveal that the presence 
of either wild-type or mutant p53 can modulate the transcriptional activity of WT1 on the 
insulin-like growth factor-1 receptor promoter. This finding led the authors to propose that 
the behavior of WTl as an oncogene or tumor suppressor may be dictated by the cellular 
p53 status[87]. We detected mutations in 24% of the samples using PCR-SSCP, similar to 
the p53 mutation rate described in the brain tumor literature[l2]. Previous studies show 
that PCR-SSCP is both a sensitive and specific method of detecting p53 mutations[lO, 
2321. However, this method does not detect the small proportion of mutations that exist 
outside of the exon 5-8 "hot spot" as well as the few mutations that do not affect DNA 
conformation[l2]. We demonstrated an association between WTl expression and p53 
mutation status in GBM samples. Tumors that possess wild-type p53 are more likely to 
express full-length WT1 than tumors possessing mutant p53. It is therefore possible that 
WTl is interacting with wild-type p53, contributing to oncogenic activity by preventing 
the cell cycle arrest and pro-apoptotic effects of p53. We have observed that silencing the 
WT1 gene can decrease glioma cell proliferation and improve response to chemotherapy 
and radiotherapy, results which are consistent with an oncogenic function of 
WTl (unpublished data). 
The majority of the tumor samples appeared to express wild-type WT1. 
Sequencing of all 10 exons of WT1 would be necessary to definitively conclude that 
mutations are absent. The detection of WT1 mRNA by primer pair 1 and not primer pair 2 
in 4 GBM samples may indicate the expression of a truncated form of WT1. This 
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phenomenon was not observed in any of the cell lines. Several such truncated forms of 
WTl have been characterized in human disease, including cancers such as prostate cancer 
and Wilms' tumor[40,212]. Previous studies of GBM did not detect any mutations in the 
WTl gene. This is not surprising considering the frequency of mutation that we report 
here is low (4150) and could have been overlooked in the studies which performed 
mutational analyses[43]. Furthermore, we detected the putative mutation by reverse 
transcriptase PCR using two primer pairs. Other studies have used either 
immunohistochemistry or real-time PCR to detect WT1, which would not detect such 
mutations[168, 1781. If confirmed to be expressed in these and other GBM samples, the 
structure and function of such putative truncated forms of WTl will need to be examined 
in future studies. 
WT1 expression did not correlate with any of the examined clinicopathologic 
characteristics of the patients, including survival. Patients with tumors that expressed 
WTl appeared to have a lower median survival than those that did not express WT1. 
However, this was not statistically significant. The fact that the majority of lower grade 
tumors also expressed WT1 would fi~rther suggest that WT1 expression is not a marker for 
tumor grade. Survival after diagnosis of GBM is currently best predicted by clinical 
markers of the patient, such as age, Karnofsky performance status, and extent of 
resection[l18,99] . In fact, recursive partitioning analyses (RPA) identified several risk 
groups based on these markers to predict prognosis[l18,214]. Unfortunately, the analysis 
of WT1 correlation with RPA groups would require a larger sample size than that included 
in this study. To date, no genetic markers clearly predict survival. GBM is a genetically 
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heterogeneous tumor, with many overlapping pathways apparently leading to a similar 
clinical outcome[l56, 13 11. Therefore, molecular changes such as EGFR 
overexpression/amplification and p53 mutation, while having established functional 
importance in glioma biology, do not correlate with prognosis[l99]. Nevertheless, our 
study demonstrates that anti-WT1 therapy may be a promising prospect for future glioma 
therapies. WT1 is expressed by over 80% of GBM specimens and does not appear to be 
expressed by normal cells. When expressed by GBM cells, WT1 is restricted to two 
isoforms and, therefore, provides an attractive target. In glioma progression, WTl appears 
to be expressed early and may therefore be a target for early treatment before the 
development of GBM. In vitro and in vivo studies show that anti-WT1 immunotherapy 
can cause lysis of WT1 expressing tumor cells and rejection of tumor challenge while 
leaving normal WTl expressing cells and tissue undamaged[l72, 1821. Recently a phase I 
clinical study demonstrated that anti-WTl immunotherapy is well tolerated and efficacious 
in patients with leukemia and solid tumors[l81]. GBM is a tumor for which there is no 
effective treatment. Surgery combined with radiotherapy can improve survival by months, 
while chemotherapy adds a modest benefit[227]. Full characterization of WTl expression 
in tumors such as GBM may establish WTl as a target for novel therapies. 
Conclusions 
The results of this study are consistent with an oncogenic function for WT1 in 
human cancer, possibly by interacting with the p53 tumor suppressor. We believe that 
WT1 expression is an aberration of normal astrocyte gene expression and is critical to 
gliomagenesis. Furthermore, the presence of WTl expression in a high percentage of 
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gliomas and its absence in normal astrocytes suggests that WTI may be a valuable marker 
for gliomas as well as a potential molecular target for this currently incurable disease. This 
study further argues for continuing efforts to determine the role of WTl in gliomagenesis. 
Future studies will focus on the function of WTl+KTS isoforms in human gliomas, 
specifically in relation to p53. 
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DOWN-REGULATION OF WILMS' TUMOR 1 EXPRESSION IN 
GLIOBLASTOMA CELLS INCREASES RADIOSENSITIVITY 
INDEPENDENTLY OF P53 
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Santos, Timothy E Van Meter, Martin R Graf, William C Broaddus 
Department of Neurosurgery, Department of Anatomy and Neurobiology, Virginia 
Commonwealth Univeristy, School of Medicine, Richmond, Virginia, USA 
Abstract 
The Wilms' tumor 1 gene is overexpressed in human glioblastoma and correlates 
with wild-type p53 status. In other cell types, WT1 inhibits p53-mediated apoptosis in 
response to DNA damaging agents. However, neither this interaction nor the relationship 
between WT1 and radiosensitivity has been studied in glioblastoma. To study this 
interaction, we generated LN-229 glioma cell lines (p53 mutant) stably expressing WTI 
isoforms and induced apoptosis by transfecting with different doses of wild-type p53 
plasmid expression vector. Constitutive expression of WTl did not protect against 
exogenous p53-mediated apoptosis. Likewise, WT1 expression did not protect against 
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endogenous p53-mediated cell death induced by radiotherapy in U87MG cells, which 
contain functional wild-type p53. We then tested the efficacy of WTl siRNA in inhibiting 
WTl expression and its effect on radiosensitivity. In T98G and LN-18 glioma cells, which 
possess p53 mutations, WTl siRNA decreased WTl protein to almost undetectable levels 
by 96 hours post-transfection. Furthermore, WTl siRNA transfection caused a 
significantly larger decrease in viability following irradiation than was seen in 
untransfected cells in both cell lines after treatment with EDso of ionizing radiation. In 
conclusion, WTl overexpression did not protect against p53-mediated apoptosis or 
ionizing radiation induced cell death. WTl siRNA increased the radiosensitivity of two 
human glioma cell lines independently of p53. Anti-WT1 strategies may, therefore, prove 
useful in improving the response of glioblastoma to radiotherapy, thus potentially 
improving patient survival. 
Introduction 
Glioblastoma multiforme (GBM) is a WHO grade IV glial tumor that carries a 
universally poor prognosis with a median survival of approximately one year after 
diagnosis[27]. Following surgery or biopsy, radiotherapy, often in conjunction with 
adjuvant chemotherapy, modestly improves survival, however glioma cell resistance to 
radiotherapy remains a major obstacle [253,224,252]. Decades of intense research have 
identified several molecular mechanisms of glioma cell radioresistance[74,28]. Despite 
these advances, a significant clinical improvement has not been realized. Therefore, a 
more complete characterization of the molecular mechanisms of resistance is necessary to 
uncover targets for novel therapies. Previous studies by our laboratory and others have 
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examined the expression of the Wilms' tumor 1 (WT1) gene in human brain tumors, 
including gliomas of all grades, and have found detectable expression in tumor cells but 
not in normal cells, suggesting an important role for WT1 in glioma biology[30, 152,43, 
168, 1781. However no studies to date demonstrate a relationship between WTl and 
resistance to commonly administered therapies in gliomas. 
WTl was originally discovered as mutated in nephroblastoma, a common pediatric 
kidney cancer also known as Wilms' tumor[23]. It was subsequently found that the wtl 
gene, located at chromosome locus 1 lp13, encodes a 52-55 kD polypeptide, the structural 
homology and function of which designate it as a zinc finger transcription factor[75]. 
Furthermore, .the messenger RNA transcript is alternatively spliced to generate four main 
isoforms, designated +I+, -I+, +I-, -I-, depending on the inclusion or exclusion of exon 5 
and nine nucleotides in exon 9 known as KTS, respectively[75]. WTl(+KTS) isoforms, 
which gliomas express[30], may be involved in RNA processing in addition to having both 
overlapping and unique transcriptional properties relative to WTl(-KTS) isoforms[38, 831. 
The functional significance of exon 5 is less well understood, but may affect its interaction 
with other proteins[200]. Although originally classified as a tumor suppressor, WT1 was 
later found to be overexpressed in many types of cancer, including breast carcinoma and 
acute leukemia, suggesting an oncogenic function for the gene[90, 1591. In fact, inhibition 
of WTl expression in human breast cancer and leukemia cell lines using antisense 
modalities leads to differentiation, decreased proliferation, and increased sensitivity to 
treatment[229, 2701. 
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One possible mechanism by which WTI could exert a tumorigenic effect in glioma 
cells is through an interaction with p53. Inactivation of the tumor suppressor p53 is a 
common aberration in human glioma progression[l2]. p53 causes cell-cycle arrest and 
apoptosis in response to DNA damage[248]. Many treatments for glioma, such as radio- 
and chemotherapy, cause DNA damage, and thus are likely to rely on p53 function for a 
therapeutic response[l33, 101. While the effect of p53 mutation on glioma response to 
radiation is uncertain, p53 status has prognostic significance in other malignant 
tumors[230,4]. In cultured glioblastoma cells, p53 mutation promotes 
radioresistance[266, 741. Studies by our laboratory and others show that introduction of 
wild-type p53 into glioma cells using various transduction methods increases 
radiosensitivity both in vitro and in vivo[l4, 8, 66, 341. Alterations in other genes, such as 
mdm2, which targets p53 for degradation, represent alternative means of inactivating p53 
in gliomas[211]. In Saos-2 osteosarcoma cells (p53 null), WT1 inhibits p53-mediated 
apoptosis induced by overexpression of wild-type p53, chemotherapy, and radiation[l36]. 
We recently reported ,that, in a large sample of glioblastoma tissue specimens, WTl 
expression correlates with the presence of wild-type p53[30]. 
This prompted us to examine if a functional relationship exists between WT1 and 
p53 in the context of glioma radiosensitivity. In this study, we investigated the effect of 
both WT1 overexpression and WTl silencing 011 p53-mediated cell death and on response 
to radiotherapy. We found that, while WT1 overexpression does not protect glioma cells 
against p53 mediated apoptosis or radiation-induced cell death, WT1 silencing sensitizes 
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glioma cells to radiation-induced arrest and death. These results suggest that WTl may be 
a potential target to improve the response of glioblastoma to radiotherapy. 
Materials and Methods 
Cell culture and tissue preparation 
The p53 status of the glioma cell lines used in this study has been previously 
determined (Table 3-1)[92], and confirmed in our laboratory by RT-PCR and cDNA 
Table 3-1. Wl and p53 status of the glioblastoma cell lines used in this study 
Cell line p53 status (codon)[92] WT1 mRNA / 18S[30] 
U87MG wild-type OkO 
T98G mutant (237, Met-lle) 103.61 k 7.9 
LN-18 mutant (238, Cys-Ser) 214.70 + 20.9 
LN-229 mutant (98, Pro-Lys) 0 k 0 
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LN-229, U87MG, LN-18, and T98G human glioma cells were obtained from American 
Type Culture Collection and were grown and passaged in Dulbecco's modified Eagle's 
medium (DMEM) containing 10% fetal bovine serum, glutamine, non-essential amino 
acids, and 1% penicillin-streptomycin in a humidified atmosphere of 5% C02.  Total RNA 
was isolated from cell lines using the Trizol extraction protocol (Invitrogen). The 
concentration of RNA was determined by spectrophotometry. Protein was extracted from 
cell lines using SDS buffer (50 mM Tris-C1, 1% SDS, 10% glycerol) supplemented with 
protease inhibitors. The concentration of protein was determined by DC protein assay 
(Bio Rad). 
Plasmid construction and transient transfection 
WT1 expression plasmids (in pcDNA3, Invitrogen) containing either WTI(+/+) or 
WTI(-/+) isoforms were kindly provided by Dr. Charles T. Roberts, Jr. and have been 
described previously[87]. Expression plasmids containing wild-type p53 (in pHCMV- 
Neo-Bam) were kindly provided by Dr. Sumitra Deb and have also been previously 
described[39]. Cells were plated in triplicate at a density of 2 X lo5 in six well plates and 
allowed to attach overnight in DMEM without penicillin/streptomycin. Cells were 
transfected with a mixture of 3 p1 Lipofectamine 2000 (Invitrogen) and plasmid diluted in 
500 p1 DMEM without fetal bovine serum or penicillin-streptomycin and incubated for 4 
hours at 37" C. After 4 hours, cells were supplemented with 1.5 ml DMEM with 10% fetal 
bovine serum without penicillin-streptomycin. Twenty four hours after transfection, the 
conditioned media was removed and replaced with 2.0 ml fresh DMEM with 10% fetal 
bovine serum without penicillin/streptomycin. 
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Short interfering RNA transfection 
Transfections with WT1 siRNA were carried out using the pre-designed 
siGENOME SMARTpool containing 4 siRNA sequences directed against WTl 
(Dharmacon). A pool of 4 non-targeting siRNA sequences (siCONTROL Non-Targeting 
Pool, Dharmacon) was used as a control and will be referred to as siscramble. Cells were 
plated at a density of 2.5 X lo5 cells in six well plates and allowed to attach overnight. 
Cells were then transfected using Oligofectamine (Invitrogen) diluted in 1 ml l x  Opti- 
MEM Reduced Serum Medium (Invitrogen) supplemented with 1 % penicillin1 
strepton~ycin. After a 4 hour incubation at 37OC, 500 pL of 3x FBSIOpti-MEM solution 
was added to each well. The final siRNA concentration was 100nM. 24 hours after 
transfection, cells were trypsinized, resuspended in fresh media, and either lysed for 
protein1RNA extraction or re-plated for clonogenic cell survival assays and luminescent 
cell viability assays. 
Generation of stable transfectants 
LN-229 and U87MG cells were plated at a density of 2 X 1 o5 in six well plates and 
allowed to attach overnight. Cells were transfected with 1.0 pg WT1 isoform expression 
vectors as described above for transient transfection. Forty eight hours after transfection, 
cells were selected in DMEM containing 600 pglml Geneticin (Invitrogen) for LN229 and 
200 pglml for U87MG. Selection media was exchanged every 4 days. 
Irradiation 
Forty eight hours after siRNA transfection or after generation of stable 
transfectants, cells were treated at room temperature with y-irradiation using a Cesium- 
source Mark I Irradiator (Cs- 137,4.149Gy/min) at indicated doses. 
Western blot analysis 
For protein analysis of cells transfected with WTl, 10 pg of total protein lysate 
were separated by SDS-PAGE and transferred to nitrocellulose membrane as per 
manufacturers' protocol (Invitrogen). The membrane was then blocked with 5% nonfat 
milk solution for 1 hour at room temperature. Rabbit anti-WT1 polyclonal antibody (1 :200 
dilution, C- 19, Santa Cruz Biotechnology), mouse anti-p53 monoclonal antibody (1 : 1000, 
Ab-6, Oncogene Research Products), and mouse anti-p21 monoclonal antibody (1 :200, 
DakoCytomation) were diluted in blocking buffer. The membranes were incubated with 
primary antibodies overnight at 4°C. The membranes were washed six times in Tris 
buffered saline containing 0.05% Tween-20 before and after a one hour incubation at room 
temperature with horseradish peroxidase-conjugated anti-rabbit secondary antibody 
(1 : 1000, Rockland, Inc.) for WTl, and anti-mouse secondary antibody (1 :2000, Rockland, 
Inc.) for p53 and p21. Blots were developed using the ECL Detection System (Amersham 
Biosciences). Anti-Cyclophilin A monoclonal antibody (1 : 1000, Upstate Biotechnology) 
was used as a control for protein loading. 
Trypan blue exclusion viability assay 
After treatment, cells were gently trypsinized from the culture surface, centrifuged, 
and the cell pellet resuspended in 1 ml of DMEM. A 1 :5 dilution of cells was made with a 
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solution containing 30 yl 0.4% trypan blue in a total volume of 100yl. Viable cells, which 
had excluded the dye, were counted by light microscopy. All treatments were performed 
in triplicate. 
Luminescent viability assay 
Cells were plated in 5 - 10 replicates per treatment group in white 96 well plates at 
a density of 1000 cells. At the specified time after treatment, CellTiter-Glo Luminescent 
Cell Viability Assay (Promega) was performed according to the protocol supplied by the 
manufacturer. Luminescence was detected by Lumi Star Luminometer (BMG). Percent 
survival was calculated by taking the relative luminescence unit of each irradiated replicate 
of a treatment group and dividing it by the average of the corresponding non-irradiated 
treatment group. 
Detection of apoptosis 
After treatment, cells were trypsinized, washed with PBS, and fixed for 30 minutes 
in 1 % paraformaldehyde at a concentration of 1-2 X 1 o6 cells/ml. Prior to analysis, fixed 
cells were stored at 4" C in 70% ethanol. DNA cleavage was used as an indicator of 
apoptosis. Treated cells were subjected TUNEL (APO-DIRECT, BD Biosciences) 
followed by flow cytometry (FACScanto, BD Biosciences) to detect strand breaks. 
Threshold level for forward scatter was set to exclude cellular debris and TUNEL-positive 
cells were measured in the FL-2 channel (FITC). 
Clonogenic survival assay 
Following siRNA transfection, 1 X 1 o2 LN- 18 cells were plated in triplicate in six 
well plates. Plates were irradiated 48 hours after transfection as described above. Eight 
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days after irradiation, cells were fixed for 30 minutes in methanol and stained with 50% 
Giemsa for one hour. Cells were then washed with distilled water and colonies consisting 
of 2 50 cells were counted. 
Statistical analysis 
Differences between multiple treatment groups were analyzed by analysis of 
variance (ANOVA) using the JMPIN 4.0.4 (SAS Institute, Inc.) software. Tukey- Kramer 
honestly significant difference test (HSD) was performed as a post-hoc analysis. 
Differences between only two treatment groups were analyzed by Student's t-test. 
Results 
LN-229 glioma cells undergo apoptosis in response to p53 overexpression. To 
examine the functional relationship between WTl and p53, we developed a glioma cell 
model of p53 mediated apoptosis. LN-229 glioma cells do not express endogenous 
WTl[30] and harbor a p53 mutation. Transfection of LN-229 cells with increasing 
amounts of wild-type p53 expression vector led to an increase in p53 protein expression 
and a concomitant up-regulation of the p53 target gene, p21, indicating that the exogenous 
wild-type p53 is functional (Figure 3-1A). Increasing amounts of wild-type p53 
expression vector resulted in a decrease in cell viability relative to cells transfected with 
the empty vector, which was maximal at a dose of 0.1 pg, and still present at 0.04 pg 
(Figure 3-1B). The decrease in viability of cells transfected with p53 relative to empty 
vector was most prominent at 4 days after transfection (Figure 3-1 C). Based on the above 
results, we chose to focus the subsequent experiments on the 0.1 pg p53 treatment dose, 
and to examine viability at four days after transfection. To determine if the cell death 
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induced by p53 was due to apoptosis, LN-229 cells were transfected with 0.1 pg p53 and 
subjected to to terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate 
nick end-labeling (TUNEL) analysis to detect DNA cleavage which is a hallmark feature 
of apoptosis. Untransfected control and cells transfected with vector alone exhibited 
minimal DNA cleavage (1.8 and 1.7 %, respectively, Figure 1 D). There was a significant 
increase in TUNEL positive cells after p53 transfection (1 0.5 %, p = 0.007, Figure 3-1 D). 
This suggests that LN-229 underwent increased apoptosis in response to transient p53 
expression. 
Figure 3-1. Transient transfection of p53 in LN-229 human glioblastoma cells. A. 
LN-229 cells were transfected with increasing doses of p53 plasmid. Protein was extracted 
24 hours after transfection. Western blot demonstrated p53 protein expression and up- 
regulation of the p53 target gene, p21. Anti-cyclophilin A was used to estimate equal 
protein loading. B. LN-229 cells were transfected with increasing amounts of p53 
plasmid. Four days after transfection, cells were trypsinized and analyzed for cell viability 
by trypan blue exclusion assay. All treatments were performed in triplicate. C. LN-229 
cells were transfected with 0.1 pg p53 plasmid. Cells were trypsinized at 1 ,2,4,  and 6 
days after transfection and analyzed by trypan blue exclusion assay. All treatments were 
performed in triplicate. D. LN-229 cells were transfected with 0.1 pg p53. Four days 
after transfection cells were subjected to TUNEL. Cells were then analyzed by FACS to 
detect DNA cleavage indicative of apoptosis (X-axis, FITC). Anotated numbers represent 
percentage of cells positive for apoptosis. The graphs are respresentative of treatments 
performed in triplicate. The experiment was repeated with similar results. Left panel, 
LN229 untransfected control; middle panel, LN229 + empty vector; right panel, LN229 
+p53, CypA cyclophilin A; VC vector control. 
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Stable expression of WT1 isoforms does not protect LN-229 cells from p53- 
induced cell death. Using a liposomal delivery system, we generated pooled LN-229 
stable transfectants expressing either empty pcDNA3 vector or pcDNA3 containing 
WTl(+/+) or WT1(-/+) isoforrns, which are the isoforms expressed in human glioblastoma. 
These cells were named LN229.VC, LN229.+/+, and LN229.-/+, respectively. After 
maintenance for several months in selection media, the cell lines were analyzed for WTl 
isoform expression by western blot. LN229.VC did not express detectable WT1 protein, 
while LN229.+/+ expressed a 55 kDa protein corresponding to higher molecular weight 
WTl(+/+) relative to LN229.-/+ which expressed the 52 kDa WT1(-/+) protein (Figure 3- 
2A and C, lanes 1, 3, and 5). To test the effect of WT1 expression on p53-mediated 
apoptosis, the cell lines were transfected with either empty vector or wild-type p53 at doses 
of both 0.1 pg and 0.04 pg. Cells transfected with empty vector expressed baseline levels 
of p53 protein which is expected as p53 mutations cause stabilization of the protein[5] 
(Figure 3-2A and C, lanes 1,3,  and 5). Cells transfected with p53 expressed very high 
levels of p53 and showed up-regulation of p21 (Figure 3-2A and C, lanes 2 ,4 ,  and 6). 
Four days after transfection, there was no difference in percent viability between the stable 
cell lines after transient p53 expression determined by trypan blue exclusion at either the 
0.1 pg or 0.04 pg dose (p = 0.19 and 0.67, respectively, Figure 3-2C and D). 
Figure 3-2. Effect of transient p53 expression in LN-229 cells stably transfected with 
WT1 isoforms. LN-229 cells expressed p53 and p21 after transfection with 0.1 pg (A) 
and 0.04 pg (C) p53 plasmid. Blots were reprobed with anti-cylcophilin A to control for 
equal protein loading. Trypan blue exclusion assay depicting the change in % viability 
after transfection with 0.1 pg (B) or 0.04 pg (D) p53 plasmid. Y axis depicts change in 
viability between cells transfected with p53 and cells transfected with empty vector. 
LN229.VC, LN229 cells stably expressing empty vector; LN229.+/+, LN229 cells stably 
expressing WT1 (+I+) isoform; LN229.4, LN229 cells stably expressing WTl (-I+) 
isoform Error bars represent the standard error (B) or standard deviation (D). VC, vector 
control; CypA, cyclophilin A. 
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Stable expression of WT1 isoforms does not protect against radiation induced cell 
death. We then tested the effect of WTl expression on an endogenous p53 response. 
U87MG cells have wild-type p53 status and undergo functional p53 signaling pathways 
following treatment with ionizing radiation[92, 2541. U87MG cells also do not express 
WT1[30]. We generated pooled U87MG cell lines stably expressing either empty vector, 
WTl(+/+), or WTl(-I+), referred to as U87.VC, U87.+/+, and U87.-/+, respectively. 
Western blot showed that U87.VC did not express detectable WTl protein, while U87.+/+ 
and U87.-/+ expressed WTl isoforms of their corresponding molecular weights (Figure 3- 
3A, top panel, lanes 1,3, and 5). Twenty four hours after exposure of the cells to 6 Gy of 
ionizing radiation, there was detectable up-regulation of p53 protein relative to non- 
irradiated cells (Figure 3-3A, bottom panel). Irradiation caused a time dependent decrease 
in viability of the U87MG cells reaching 45% relative to non-irradiated cells at 7 days after 
treatment, however stable expression of WTl did not cause a change in percent viability 
(Figure 3-3B). The experiment was repeated 3 times at the 7 day time point with similar 
results (Figure 3-3C). 
Figure 3-3. Effect of ionizing radiation on U87MG cells, which express wild-type p53, 
stably transfected with WT1 isoforms. A. U87MG cells were transfected with 
expression plasmids containing WT1 isoforms, and selected for stable expression. Pooled 
stable cell lines were treated with 6 Gy ionizing radiation. Protein was extracted 24 hours 
after irradiation. Western blot demonstrated WT1 expression in U87MG after stable 
transfection (top panel). Western blot demonstrated p53 expression in U87 stable 
transfectants after treatment with 6 Gy ionizing radiation (bottom panel). B. U87MG cells 
were treated with 6 Gy ionizing radiation. Viability assay based on cellular content of 
ATP demonstrated a decrease in viability of the U87MG stable transfectants at 1 ,  3, 5, and 
7 days relative to non-irradiated cells. All treatments were performed in quintuplicate. C. 
ATP viability assay demonstrated a decrease in viability of the U87MG stable transfectants 
at 7 days after irradiation (n = 3). 
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WT1 siRNA transfection increased sensitivity to radiotherapy. We then 
determined if anti-WT1 strategies would sensitize glioblastoma cells to radiotherapy 
independently of p53-mediated cell death pathways. We used T98G and LN-18 glioma 
cells, both of which harbor p53 mutations and express endogenous WT1[30,92]. To 
characterize the response of these cells to radiotherapy, cells were treated with increasing 
doses of radiation and, 5 days after treatment, viability was assessed. Increasing doses of 
radiation caused a progressive decrease in percent viability relative to untreated controls in 
both cell lines (Figure 3-4A). Further analysis determined the EDso dose (dose expected to 
cause a 50% decrease) of ionizing radiation to be 7 Gy for T98G and 5 Gy for LN-18. 
Cells were then treated with the respective EDs0 dose of radiation, and percent viability 
was measured at 1 ,3,5,7,  and 9 days. In both cell lines, viability decreased to a minimum 
at 5 days after which they began to recover (Figure 3-4B). Subsequent cytotoxicity 
experiments were performed at the EDs0 doses and responses measured at 5 days post- 
irradiation. To confirm that ionizing radiation caused a decrease in the capacity for 
clonogenic survival, LN-18 cells were subjected to increasing doses of irradiation. Eight 
days after treatment, Giemsa staining demonstrated a decrease in fractional survival 
relative to nonirradiated cells with an EDso of 2 Gy (Figure 3-4C). 
We then tested the efficacy of siRNA targeting WT1 in these cell lines. T98G and 
LN-18 cells were transfected with siRNA and relative WT1 protein levels were measured 
96 hours later. Western blotting demonstrated that WTl protein expression was inhibited 
at 96 hours post-transfection in T98G (Figure 3-4D, inset) and LN-18 (Figure 3-4E, inset). 
Densitometric analysis of levels of WT1 normalized to cyclophilin A showed that WT1 
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protein expression was decreased by almost 100% at 96 hours in T98G cells and LN-18 
cells. 
To determine if WTI targeting could improve the response to radiotherapy, we 
transfected the cells with WTl siRNA and 48 hours later subjected them to EDs0 doses of 
ionizing radiation. Viability assays performed 5 days after irradiation showed a 
significantly larger decrease in viable cells pre-treated with WT1 siRNA than either 
untransfected or vehicle treated T98G (Figure 3-4D) and LN-18 cells (Figure 3-4E). T98G 
cells transfected with WT1 siRNA followed by irradiation had a 42.5% viability while 
those untransfected or treated with vehicle alone had 68.8% and 55.8%, respectively (p < 
0.0001). LN-18 cells had a 43.2% viability after combination treatment, compared to 
87.2% and 73.7% for untransfected and vehicle alone, respectively (p < 0.0001). In 
addition, WTI siRNA caused a smaller, but still significant, decrease in fractional survival 
after irradiation in LN-18 cells as measured by the clonogenic survival assay (p < 0.0001, 
Figure 3-4F). The fractional survival of cells transfected with WTl siRNA after irradiation 
was 0.38, while untransfected cells and those treated with vehicle alone had a fractional 
survival of 0.50 and 0.47, respectively. 
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Figure 3-4. Effect of ionizing radiation combined with WT1 siRNA treatment. A. 
T98G and LN-18 cells were treated with increasing doses of ionizing radiation and at 5 
days after treatment percent viability relative to non-irradiated cells was then measured by 
an ATP based cell viability assay. B. T98G and LN-18 cells were treated with their 
respective EDso of ionizing radiation and percent viability was measured at 1,3,  5,7, and 9 
days post-irradiation. C. LN-18 cells plated at very low density were subjected to 
increasing doses of ionizing radiation. After 8 days colonies were stained with Giemsa and 
counted to determine the fractional survival relative to untreated cells. T98G (D, inset) and 
LN-18 (E,inset) cells were treated with siRNA and protein was extracted at 24 and 96 
hours after transfection. Western blotting demonstrated knock-down of WT1 protein. 
Blots were re-probed with anti-cyclophilin A to control for equal protein loading. Anti- 
WTl siRNA decreased viability of T98G (D) and LN-18 (E) human glioblastoma cells 
after treatment with ionizing radiation. Cells either remained un-transfected, or were 
treated with Oligofectamine vehicle or siRNA. After 48 hours, cells were treated with 
their respective EDso of ionizing radiation. Luminescent cell viability assay was 
performed 5 days after irradiation. The data is presented as percent viability of the 
irradiated cells relative to non-irradiated controls which underwent the same transfection 
procedure. Error bars represent the standard deviation. Graphs are representative of three 
experiments with similar results. * p < 0.01 by Tukey's HSD. F. LN-18 cells were 
irradiated 48 hours after treatment with siRNA. Giemsa staining and colony counting were 
performed 8 days after irradiation (n = 3). Error bars represent the s.e.m. * p < 0.01 by 
Tukey-Kramer HSD; UT, untransfected; Of, oligofectamine alone; Si, siRNA 
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Discussion 
Based on reports in the literature, we hypothesized that WT1 would be involved in 
glioma cell response to radiotherapy by inhibiting p53-mediated apoptosis[l36]. To 
examine this possible interaction, we overexpressed WTl(+/+) and (-I+) isoforms in LN- 
229 glioblastoma cells and found that WT1 expression did not inhibit apoptosis induced by 
transient p53 transfection. Likewise, we found that WTl overexpression in U87MG cells 
did not protect against p53-mediated cell death in response to irradiation. We then used 
WT1 siRNA to silence WT1 expression in T98G and LN-18 glioblastoma cells, both of 
which harbor p53 mutations. We found that WTl silencing increased radiosensitivity as 
demonstrated by a decrease in viability and clonogenicity after treatment with ionizing 
radiation. 
The effect of WTl on apoptosis is highly variable. Both pro- and anti-apoptotic 
effects have been described, depending on the cell type and tissue studied[48, 1441. Low 
levels of WT1 inhibit apoptosis by interaction with p53[136]. In the same study, the 
functional interaction was primarily studied using the WTl(-KTS) isoforms, however a 
more modest anti-apoptotic response was observed with WTl(+KTS) isoforms as well. 
We chose to study the WTl(+KTS) isoforms in this work because we have previously 
shown that gliomas express WTl(+KTS) isoforms exclusively[30]. High levels of WT1 
induce apoptosis independently of p53 in osteosarcoma cell lines. This apoptosis is 
associated with down-regulation of the epidermal growth factor receptor (EGFR) and 
induction of p21[48,49]. However, these studies only show an effect of WT1(-KTS) 
isoforms. Nevertheless, apoptosis induced by high levels of WT1 in the stably transfected 
104 
cell lines used in this study may have masked the WT1-p53 interaction. Studies examining 
the effect of lower levels of WT1 on p53 mediated cell death in human glioblastoma cells 
are ongoing. Here we showed that the cell death associated with wild-type p53 in LN-229 
glioblastoma cells correlated with an approximately 10% increase in apoptotic cells. It is 
therefore possible that some of the decrease in viability was due to p53-dependent non- 
apoptotic mechanisms, such as cell cycle arrest, autophagy, senescence, or 
differentiation[33, 2481. No studies to date have examined the ability of WT1 to inhibit 
these p53 responses, 
WT1 also inhibits apoptosis by p53-independent mechanisms. WT1 directly 
upregulates Bcl-2 in cell lines of different p53 status[l44]. This upregulation of the anti- 
apoptotic protein protects cells from apoptosis induced by DNA damaging chemotherapy 
agents. Conversely, WTl siRNA targeting WTl(+exon5) isoforms induces apoptosis in 
leukemia cell lines which is associated with up-regulation of the pro-apoptotic Bcl-2 
family member Bax[93]. In the same study, Ito et al, demonstrate that overexpression of 
WT1 protects leukemia cells from apoptosis induced by chemotherapeutic agents which is 
associated with downregulation of Bak. In addition, WT1 modulates the expression of 
EGFR[127] and platelet-derived growth factor (PDGF)[255]. These growth factors and 
receptors participate in glioma cell resistance to radiotherapy[28, 841. The effect of WT1 
silencing on radiosensitivity observed in this study may be due to p53-independent effects 
of WT1 on the transcription of these genes. 
In addition to p53, other protein-protein interactions modulate the activity of 
WT1[210]. WT1 physically interacts with the other members of the p53 family of 
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proteins, p73 and p63[209]. In this study, Scharnhorst et al. show that WT1 inhibits p73- 
mediated transactivation, while p73 reciprocally inhibits DNA binding by WT1. Both p73 
and p63 induce apoptosis and are involved in the cellular response to ionizing 
radiation[268, 2071. WTl(+exonS) isoforms also physically bind to the prostate apoptosis 
response factor, par4, and inhibit par4-mediated cell death in response to radiation and 
chemotherapy. Par4 also modulates the function of WT1 as a transcription factor[200]. 
Therefore, the presence or absence of factors that interact with and modify the function of 
WT1 in the different cell lines used in this study could be responsible for the differential 
results obtained from the overexpression and silencing series of experiments. 
In contrast to previous studies in other non-glioma cell lines, here we show that in 
human glioblastoma cell lines, WTl does not protect against p53-mediated apoptosis 
induced by either p53 overexpression or ionizing radiation. This study documents for the 
first time that WTl in gliomas is unlikely to be functionally related to these cellular 
responses in gliomas, and underscores the reported cell and tissue type dependence of WT1 
function. Nevertheless, we show that WT1 silencing by siRNA can improve the 
radiosensitivity of glioblastoma cells independently of p53-mediated cell death pathways. 
This suggests that anti-WT1 therapies may have the potential to improve the response of 
human brain tumors to radiotherapy. Further study of the molecular mechanisms of WTl 
function in gliomas promises to identify strategies to improve glioblastoma radiosensitivity 
in an effort to improve prognosis of this difficult disease. 
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Abstract 
Wilms' tumor 1 (WT1) is overexpressed in many human cancers, including 
glioblastoma. We have previously shown that transient WT1 silencing increases 
radiosensitivity in glioma cells. Studies of non-glioma cell lines demonstrate that WT1 
promotes cell proliferation and survival. However this has not been rigorously studied in 
glioblastoma. We tested the efficacy of two sequences of short hairpin RNA (shRNA) 
directed against WTl in U251MG human glioblastoma cells and found that one sequence 
was capable of stably silencing WT1 expression. Stable WT1 shRNA expression 
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significantly decreased the proliferation of U25 1MG cells in vitro demonstrated by both 
ATP-based viability assay and tritiated thymidine uptake. Furthermore, stable WT1 
silencing caused significantly slower growth after inoculation of tumor cells 
subcutaneously in the flanks of athymic nude mice and was associated with an increased 
latency period. These studies provide proof of principle that downregulation of WT1 
causes decreased tumorigenicity of a glioblastoma cell line in vitro and in vivo, and suggest 
that WT1 may be a promising target for novel glioblastoma molecular therapies perhaps in 
combination with standard treatment modalities. 
Introduction 
Glioblastoma multiforme (GBM) is a WHO grade IV glial tumor that carries a 
universally poor prognosis with a median survival of one year after diagnosis[27]. 
Aggressive surgery, combined with radiotherapy and adjuvant chemotherapy, modestly 
improves survival; however glioma cell resistance to standard treatments remains a major 
obstacle. This is due, in part, to the high proliferative capacity and profound invasiveness 
of glioma cells[20,22]. Decades of intense research have uncovered several molecular 
mechanisms of glioma cell tumorigenicity[l34]. Despite these advances, a significant 
clinical improvement has not been realized. Therefore, a more complete characterization 
of the molecular mechanisms of tumorigenicity is necessary to uncover targets for novel 
therapies. Previous studies by our laboratory and others have examined the expression of 
the Wilms' tumor 1 (WT1) gene in human brain tumors, including gliomas of all grades, 
and have found detectable expression in tumor cells but not in normal cells, suggesting an 
important role for WTl in glioma biology[30, 178, 152,431. We have also shown that 
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WT1 silencing increases radiosensitivity of glioblastoma cell linesa. Oji et al., demonstrate 
that downregulation of WT1 using antisense oligodeoxynucleotides (ODN) decreases 
viability of glioma cells 72 hours after transfection[l78]. However no studies to date have 
extensively characterized the relationship between WT1 expression and tumorigenicity in 
gliomas. 
WTl was originally discovered as mutated in nephroblastoma, a common pediatric 
kidney cancer also known as Wilms' tumor[23]. It was subsequently found that the wtl 
gene, located at chromosome locus 1 lp13, encoded a 52-55 kD polypeptide, the structure 
and function of which designate it as a zinc finger transcription factor[l62]. Furthermore, 
the message is alternatively spliced to generate four main isoforms, designated +I+, -I+, +/- 
, -I-, depending on the inclusion or exclusion of exon 5 and nine nucleotides in exon 9 
known as KTS, respectively[75]. WT1 (+KTS) isoforms, which gliomas express[30], may 
be involved in RNA processing in addition to having both overlapping and unique 
transcriptional properties relative to WT1 (-KTS) isoforms. The functional significance of 
exon 5 is less well understood, but may affect its interaction with other proteins[200]. 
Although originally classified as a tumor suppressor, WTl was later found to be 
overexpressed in many types of cancer, including breast carcinoma and acute leukemia, 
suggesting an oncogenic function for the gene[159,90]. WT1 overexpression causes 
increased proliferation of cancer cells[239]. Inhibition of WT1 expression in human breast 
cancer and leukemia cell lines using antisense modalities leads to differentiation, decreased 
proliferation, and increased sensitivity to treatment[270, 31. Especially relevant to gliomas 
a Clark et al., "Down-regulation o f  Wilms' tumor 1 expression in. .." manuscript in prep. 
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which cause death by direct invasion and destruction of normal brain tissue, WT1 
overexpression was recently shown to increase invasion of ovarian cancer cells[95]. Based 
on the studies described above, we hypothesized that WT1 downregulation would decrease 
the tumorigenicity of glioma cells. To test the hypothesis, we utilized U25 IMG human 
glioblastoma cells, which express moderate levels of endogenous WTl. We generated 
U25 1 MG cells stably transduced with either empty vector or WT1 shRNA and examined 
the effect on proliferation, invasion, and in vivo tumor growth. 
Materials and Methods 
Plasmid construction 
Short interfering RNA (siRNA, Dharmacon) was tested for efficacy in cell culture 
per the manufacturer's protocol (data not shown). Forward and reverse oligos were 
generated using the provided sequence. Plasmid WT1 shRNA expression vectors were 
constructed according to the manufacturers' protocol (pSUPER.retro.neo+gfp, 
OligoEngine). Briefly, the pSUPER vector was linearized using HindIII and BclII 
restriction enzymes. The annealed forward and reverse oligos were ligated into the 
linearized vector with T4 DNA ligase (New England Biolabs, Inc.) to generate either 
empty pSUPER vector or pSUPER.shWT1 expression vector. The vectors were then used 
to transform DHSalpha bacteria (Invitrogen) selected with ampicillin. Plasmid purification 
was performed using the QIAGEN plasmid mini kit (Qiagen). The presence of positive 
clones was confirmed by EcoRI and HindIII digestion and sequencing. The packaging cell 
line 293 T was then transfected with either empty pSUPER vector or pSUPER.shWT1 
vector in addition to pCL-ampho packaging vector and pME-VSVg envelope vector using 
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FuGENE 6 transfection reagent according to the manufacturers' protocol (Roche). After a 
two day incubation at 37" C, media containing the retrovirus was harvested, filtered, and 
stored in aliquots at -80" C. 
Cell culture, viral transduction, sample preparation 
U25 1 MG, LN-18, and U87MG human malignant glioma cells were obtained from 
American Type Culture Collection and were grown and passaged in Dulbecco's modified 
Eagle's medium (DMEM) containing 10% fetal bovine serum, 1 % glutamine, 1 % non- 
essential amino acids, and 1% penicillin-streptomycin in a humidified atmosphere of 5% 
COz. For transduction, cells were plated in six well plates at a density of 0.25 X lo6 cells 
per well and allowed to attach overnight. Media was then replaced with 0.5 ml of infection 
media (without fetal bovine serum) containing virus. Cells were incubated with gentle 
agitation for 2 hours at which time 1.5 ml of media (with serum) was added to cells. After 
viral transduction, cells were maintained in DMEM supplemented with 300 pglml of G418 
(Geneticin, Invitrogen) which was exchanged every three days with fresh selection media. 
Total RNA was isolated from cell lines using the Trizol extraction protocol (Invitrogen). 
The concentration of RNA was determined by spectrophotometry. Protein was extracted 
from cell lines using SDS buffer (50 mM Tris-C1, 1% SDS, 10% glycerol) supplemented 
with protease inhibitors. The concentration of protein was determined by DC protein assay 
(B ioRad). 
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Western blot analysis 
20 - 4.0 pg of protein was separated on a 4-1 2% Bis-Tris NuPAGE gel and 
subjected to electrophoresis as per the manufacturer's protocol (Invitrogen). Protein was 
transferred to a nitrocellulose membrane. The membrane was then blocked with 5% nonfat 
milk solution for 1 hour at room temperature. Mouse anti-WT1 monoclonal antibody 
(1 :200 dilution, DakoCytomation) was diluted in blocking buffer. The membranes were 
incubated with primary antibodies overnight at 4°C. The membranes were washed six 
times in Tris buffered saline containing 0.05% Tween-20 before and after a one hour 
incubation at room temperature with horseradish peroxidase-conjugated anti-mouse 
secondary antibody (1: 1000, Rockland, Inc.) for WT1. Blots were developed using the 
ECL Detection System (Amersham Biosciences). Anti-Cyclophilin A monoclonal 
antibody (1 : 1000, Upstate Biotechnology) was used as a control for protein loadii~g. 
Proliferation assays 
Cells were plated in 5 replicate wells of 96 well tissue culture treated plates at a 
density of 0.5 X lo3 cells per well. Cell viability was measured using the CellTiter-GLO 
Luminescent Cell Viability Assay (Promega) at designated time points after plating. 
Relative luminescence was detected on a Lumistar luminescence plate reader (BMG 
Technologies). Tritiated thymidine OH-T~R)  uptake was analyzed by plating in 
quintuplicate 0.5 X lo3 cells per well in 96 well, flat bottom tissue culture plates and 
pulsing with 1 pCi of 3 ~ - ~ d ~  at 4 days (Arnersham Biosciences). Cells were cultured for 
an additional 18 hours and then stored at -80" C. Incorporation of H-TdR was used as a 
measure of proliferation and was analyzed using a 96-well plate harvester and a beta-plate 
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reader (Packard). Data are expressed as mean counts per minute (CPM) of quintuplicate 
experimental cultures. 
Invasion assay 
A modified 96 well chemotaxis assay (Neuroprobe, Inc.) was used to monitor 
tumor cell invasiveness. Assay chambers consisted of a fitted manifold with a porous 
polycarbonate membrane (8 pM pores), pre-coated for 45 minutes at 37 "C with 25 pg/ml 
growth factor reduced Matrigel (BD Biosciences; 50 pllwell). Cells were plated in 5 
replicate wells at a density of 0.5 X lo4 cells per well. After 48 hours, media and cells 
which had not invaded through the membrane were removed from the upper surface of the 
manifold and 0.05 M EDTAJPBS solution added to each well, incubated at 37 "C for 15 
minutes, prior to centrifugation of the plate at 300 X g. Cell growth medium was removed 
from the lower chamber and fresh media added to each well. Collected cells in the lower 
chamber were lysed for 10 minutes in Cell-titer Glo ATP viability assay reagents, 
following the manufacturer's protocol (Promega). Cell lysates were transferred to opaque, 
white-walled 96 well plates and relative luminescence detected on a Lumistar 
luminescence plate reader (BMG Technologies). Two replicate independent assays were 
performed. 
In vivo tumor growth in nude mice 
For inoculation, cells were first washed with sterile PBS and .then harvested by 
trypsin-EDTA treatment. The dispersed cells were resuspended in sterile PBS and adjusted 
to 3 x lo7 cellsJm1. Then 200 pl(6 x lo6 cells) of the cell suspension was injected 
subcutaneously (s.c.) in the middle of backs of male 4 -6 week old athymic BALBJc nu/nu 
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mice (Harlan Sprague Dawley, Inc.). For each of the three cell lines, 5 mice were 
inoculated. Tumor size after injection was measured starting four days after inoculation 
every two days for six weeks by dial-caliper and tumor volumes were calculated as (length 
x (width2)) 12. Mice were euthanized when the tumor had reached 800 mm3. After 
euthanasia, tumors were dissected from the skin and underlying muscle, snap frozen, and 
stored at -80" C. Tissue was homogenized and protein extracted by SDS buffer and 
sonication. Two replicate independent experiments were performed for a total of 30 mice. 
Histological analysis 
Tumor tissues were fixed in formalin, embedded in paraffin, and 5 pm serial 
sections were prepared. A representative section was stained with hematoxylin and eosin 
for histopathology. All slides were read in a blind manner. Microscopy was performed at 
the VCU - Dept. of Neurobiology & Anatomy Microscopy Facility, supported, in part, 
with funding from NIH-NINDS Center core grant (5P30NS047463). 
Statistical analysis 
Differences between two groups were analyzed by Student's t test. Differences 
between three groups were analyzed by ANOVA followed by Tukey- Kramer honestly 
significant difference test (HSD) as a post-hoc analysis. Differences between in vivo 
growth rates were analyzed by repeated measures ANOVA. 
Results 
WT1 shRNA decreased proliferation. U25 1 MG cells expressed high levels of 
WT1 (Figure 4-1). 
Figure 4-1. U251MG glioblastoma cells expressed WT1 protein. 40 pg protein 
extracted from U25 1 MG, LN-18, and U87MG cells was separated by SDS-PAGE and 
examined for WTl expression by western blot. PC3 prostate carcinoma cell extract was 
used as a positive control for WTl expression. U25 1MG cells expressed high levels of 
WTl protein. U87MG cells did not express WT1 protein as we have previously shown 
and served as a negative control. Anti-cyclophilin A antibody demonstrated low protein 
loading in LN-18 cells, however a faint WTl band is observed. CypA, cyclophilin A 
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Although protein loading was unequal, LN-18 cells expressed detectable WTl protein 
while U87MG cells did not. These results confirm our previous characterization of WT1 
expression in these cell lines[30]. We tested two sequences of shRNA targeting WTl, 
referred to as 2N and 4N, for efficacy of WTl silencing in both U25 1MG and LN-18. 
After three weeks of maintenance in selection media, protein was extracted and analyzed 
by western blot for WT1 expression. Viral transduction with 4N shRNA resulted in a 
marked decrease in WTl protein expression in both cell lines relative to cells transduced 
with empty vector, while 2N did not (Figure 4-2a). All subsequent experiments utilized 
4N shRNA transduced cells (now referred to as U25 1 .Sh and LNl8.Sh). Each treatment 
group was maintained as a pooled population of cells to eliminate the possibility of clonal 
differences in growth characteristics affecting the growth measurements. Viral 
transduction with either empty vector or WTl shRNA did not cause a change in 
morphology of the cells relative to their respective parental cell line (Figure 4-2b). In 
U25 1 MG cells transduced with either empty vector (U25 1 .VC) or WT1 shRNA containing 
vector, the majority of cells expressed green fluorescence protein (GFP) demonstrating 
stable expression of the plasmid vector (Figure 4-2c). The effect of WTl silencing on in 
vitro proliferation was examined by ATP-based viability assay at 0, 1, 3, 5, and 7 days. 
U251 .Sh cells proliferated at a significantly slower rate than U25 1 .VC cells ( p  < 0.0003, 
Figure 4-2d). Tritiated thymidine incorporation performed at 5 days confirmed the 
decrease in proliferation (p = 0.0003, Figure 4-2e). WT1 knock-down was maintained 
throughout these experiments (Figure 4-2e, inset). WT1 silencing in LN-18 cells caused a 
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less dramatic, but still statistically significant decrease in proliferation over the course of 5 
days (Figure 4-20. 
Figure 4-2. WT1 silencing decreased in vitro proliferation. A. U25 1 MG and LN-18 
cells were virally transduced with one of two sequences of WTl shRNA. After several 
weeks of selection pressure, protein was extracted from the pooled population and 
analyzed for WTl silencing by Western blot. B. Phase contrast microscopy demonstrates 
the morphology of the parental and virally transduced cells. C. Fluorescence microscopy 
demonstrates that the majority of U25 1 MG cells transduced with the expression vector 
stably expressed GFP (top panel). Light microscopy images are provided for comparison 
(bottom panel). Magnification is 40X. D. ATP-based cell viability assay performed on 
U25 1MG cells at 0, 1, 3, 5, and 7 days after plating demonstrates the decrease in 
proliferation of U25 1 .Sh cells relative to cells transduced with empty vector (U25 1 .VC). 
*p < 0.0003 E. 3 ~ - ~ d ~  uptake assay performed at 5 days confirms that U25 1 .Sh cells are 
proliferating more slowly. Inset depicts western blot analysis of WT1 expression 
confirming that WTl silencing was maintained at the time of the experiment. *p = 0.0003 
F .  ATP-based cell viability assay demonstrates the proliferation of LN18.Sh cells at 0, 1, 
3, and 5 days after plating relative to LN18.VC cells. *p < 0.05 
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WT1 silencing decreased invasion. Glioblastoma cell invasion into normal brain 
is a major contributor to the tumorigenicity of these cells. We therefore analyzed the affect 
of WT1 silencing on glioblastoma cell invasion by in vitro Matrigel invasion assay. After 
48 hours, 63% fewer viable cells were present in the lower chamber of the in vitro invasion 
assay apparatus in U25 1 .Sh cells relative to U25 1 .VC cells ( p  = 0.01, Figure 4-3). 
Figure 4-3. WT1 silencing decreased in vitro invasion. U25 1 parental, U25 1 .VC, and 
U25 I .Sh cells were plated in the top chamber of a modified chemotaxis manifold on a 
Matrigel-coated porous membrane. Two days after plating, the amount of cells that had 
invaded through the membrane was quantified by viability assay and demonstrated that 
U25 1 .Sh cells exhibited lower invasion through the membrane. *p = 0.01, RLU, relative 
luciferase units 
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WT1 silencing decreased growth of tumor xenografts in nude mice. The 
ultimate test of tumorigenicity is in vivo tumor formation. To test this, U25 1 .Sh cells were 
used to inoculate five nude mice subcutaneously in the flank and compared to five mice 
inoculated with U25 1 parental and five mive inoculated with U25 1 .VC cells. U25 1 
parental and U25 1 .VC cells formed tumors with very little latency period. U25 1 .Sh 
tumors remained undetectable for a significantly longer period of time relative to either 
parental U25 1 cells or U25 1 .VC cells (9 vs. 4 days, p = 0.01). Eventually tumors formed 
in 100% of animals inoculated with either of the three cell lines. At all days, mice bearing 
U25 1 .Sh tumors had visibly smaller tumors than either U25 1 parental or U25 1 .VC bearing 
animals (Figure 4-4a). At 22 days post-inoculation, when the first animal was euthanized 
for a tumor > 800 mm3, U25 1 .Sh tumors were significantly smaller than U25 1 parental or 
U25 1 .VC tumors (U25 1 .Sh, 156.0 mm3; U25 1, 570.6 n1m3; U25 1 .VC, 720.5 mm3, p = 
0.0004). U25 1 parental and U251 .VC tumors were not significantly different (p > 0.05). 
Analysis of the growth curves revealed a significant decrease in growth rate of U25 1 .Sh 
tumors relative to U25 1 parental and U25 1 .VC tumors (Figure 4-4b top panel, p < 0.0001). 
Despite differences in growth rate, 100% of tumors reached 800 mm3 by 34 days post- 
inoculation and were euthanized. However, U25 1 .S11 tumors reached 800 mm3 in 3 1.3 
days while U25 1 parental and U25 1 .VC tumors took 26.4 and 23.6 days, respectively (p = 
0.0028). A second independent experiment was performed with similar results (Figure 4- 
4b, lower panel). Histologic analysis of a subset of tumors demonstrated that all tumors 
examined were densely cellular. Although the sample size is too small to derive any 
conclusions, the U25 1 .Sh tumors appeared to contain less cells undergoing mitosis, 
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consistent with a lower proliferation rate(Figure 4-4c). Since the U25 1 .Sh tumors 
eventually formed large tumors, western blotting was performed on the excised tumors and 
probed for WT1 expression to determine if WT1 shRNA expression had been lost. While 
WT1 silencing was maintained at the time of inoculation in cell lines growing in culture, 
all U25 1 .Sh tumors regained WT1 expression by the time they had reached 800 mm3 
(Figure 4-4d). 
Figure 4-4. WT1 silencing decreased in vivo growth rate. Five athymic nude mice each 
were inoculated with 6 X 1 o6 U25 1 parental, U25 1 .VC, and U25 1 .Sh cells subcutaneously 
in the middle of the back. Tumor growth was measured every two days until tumor had 
reached 800 mm3. A. Photograph taken of representative animals from each group at day 
16 post-inoculation demonstrated the difference in tumor size of U25 1 .Sh tumors relative 
to U25 1 parental and U25 1 .VC tumors. The scalpel handle is shown for scale. B. Growth 
curve demonstrated the slower growth rate of U25 1 .Sh tumors. The in vivo growth 
experiment was repeated with similar results (lower panel). Error bars represent the 
standard error. C. When tumors reached 800 mm3, tumors were excised and forrnalin 
fixed for tissue sectioning and hematoxylin and eosin staining. Histopathology 
demonstrated densely cellular tumors. Arrows indicate mitotic bodies. Magnification is 
indicated at the left margin. D. After excision, tumor tissue was snap frozen and protein 
extracted for western analysis. Representative western blot of excised tumor protein 
lysates demonstrated that WT1 was expressed by all tumors. WTI expression in protein 
extracts from cells growing in culture is demonstrated for comparison. 
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Discussion 
To examine the affect of WT1 expression on glioblastoma cell tumorigenicity, we 
generated U25 1MG and LN-18 human glioblastoma cells stably expressing shRNA 
targeting WTl. Viral transduction with WT1 shRNA was capable of stably silencing of 
the WTl gene over the course of multiple passages. WTl silencing significantly decreased 
the proliferation of U25 1 MG and LN-18 cells in culture. Interestingly, we observed a 
decrease in viable cells that had migrated through a Matrigel-coated membrane suggesting 
that WTl silencing decreased the invasive potential of U25 1MG cells. Most importantly, 
WT1 silencing was associated with increased tumor latency and decreased growth rate in 
vivo after inoculation in athymic nude mice. 
The role of WT1 in glioblastoma has not been extensively characterized. The 
results of this study suggest that one function of WTl in glioblastoma is to maintain the 
high proliferative rate characteristic of the tumor. One previous study describes a decrease 
in viability 72 hours after treatment of U87MG, A172, and T98G glioblastoma cells with 
WTl antisense ODN[178]. Although their results correlate well with the cell proliferation 
results presented here, our laboratory has shown in this study and previously that U87MG 
cells do not express endogenous WT1[30]. Strangely, the manuscript does not include a 
depiction of U87MG protein expression or of the efficiency of WT1 knock-down in any of 
the cell lines examined[l78]. Studies of other cancer cell types also support a role for 
WTl in increasing proliferation. Inhibition of WTl expression by antisense ODN in K562 
and MM6 leukemia cell lines causes decreased proliferation and viability. Zapata- 
Benavides et a1[270] show that WT1 antisense ODN treatment of breast cancer cell lines 
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causes decreased proliferation which is associated with decreased cyclin Dl ,  however 
direct transactivation is not demonstrated. Furthermore, in MCF-7 and MDA486 breast 
cancer cells, WTl directly up-regulates the expression of the proto-oncogene c-myc, a 
known stimulator of proliferation[76]. These in vitro functional studies are potentially 
clinically relevant as high WTl expression in both leukemia and breast cancer correlates 
with worse prognosis[90, 1591. 
Our results suggest a role for WTl in glioblastoma cell invasion. However, due to 
the strong anti-proliferative effect of WT1 silencing observed in U25 1MG cells, we cannot 
discount the possibility that the difference in viable cells that had migrated through the 
Matrigel-coated membrane is due to a difference in proliferation and not invasion. 
Although the relationship between WT1 and glioblastoma cell invasion has not been 
previously reported, recent evidence suggests a role for WTl in cancer cell migration and 
invasion. Jomgeow et a1 demonstrates that WT1 increases the invasion of TYK ovarian 
cancer cells[95]. WT1 overexpression causes an increase in cell invasion as measured by 
in vitro invasion assay. This is associated with a change in morphology possibly due to 
WTl -mediated changes in cytoskeletal components; a decrease in a-actinin and cofilin 
expression and an increase in gelsolin expression. A separate study demonstrates that 
WTl regulates the E-cadherin promoter, a cell adhesion molecule involved in cancer cell 
invasion[85]. Studies to confirm the role of WTl in glioblastoma cell invasion and to 
determine the underlying molecular mechanism are ongoing in the laboratory. 
Several studies have examined the effect of WTl over-expression on in vivo tumor 
growth in nude mice. The results, however, have been contradictory. WTl (-KTS) isoform 
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expression in transformed baby rat kidney cells increases tumor growth rate, while 
WTl(+KTS) isoforms suppress tumor growth[l50]. Transfection of all isoforms of WTl 
in Wilms' tumor cells increases tumor latency and decreases growth rate. Stable 
expression of WTl (-KTS) in prostate cancer cells decreases in vivo tumorigenicity which 
is associated with increased apoptosis and decreased expression of the WTl target Bcl- 
2[5 11. In contrast to in vitro data described above in breast cancer cells, transfection of 
MDA-MB-23 1 breast cancer cells with WTl completely prevents tumor formation in nude 
mice which is associated with decreases p-catenin expression and activity. Likewise 
subcutaneous or intraperitoneal injection of Ml murine leukemia cells overexpressing 
WTl (+KTS) results in decreased tumor formation in severe combined immunodeficient 
mice[226]. To our knowledge, ours is the first study to examine the affect of WTl 
silencing on in vivo tumor growth. The results of our study relative to others may be 
indicative of the well described cell-type specific responses of WTl or may reflect 
differences inherent in comparing the response of overexpression of an exogenously 
applied gene versus down-regulation of an endogenously expressed gene. 
Although stable expression of WTl shRNA caused increased tumor latency and 
decreased tumor growth in vivo, within 34 days the U25 1 .Sh tumors reached 800mm3. 
The outgrowth of a tumor cell subpopulation could explain the accelerated growth rate 
after a latency period. In fact, at the time of harvest, all tumors had regained WTl 
expression as demonstrated by western blot. Protein contamination by non-tumor cells in 
the tissue sample was not likely responsible for this observation as histologic examination 
demonstrated that anaplastic tumor cells comprised the vast majority of the specimen. 
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This suggests that the in vivo environment provided a selective pressure for the outgrowth 
of clones which had lost WTl shRNA expression allowing increased proliferation. This 
finding clearly demonstrates the importance of WT1 in supporting glioblastoma cell 
proliferation and provides further evidence in support of an oncogenic function of WTI in 
glioblastoma. Future studies focused on modalities capable of maintaining full WTI 
silencing potentially may be able to halt in vivo experimental glioblastoma growth. 
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CHAPTER 5. 
GENERAL DISCUSSION 
In this series of studies we aimed to characterize the expression of WT1 in human 
glioblastoma and determine its function therein. This manuscript presents several novel 
findings pertaining to the role of WTl in glioma biology. We show for the first time that 
80% of glioblastoma tissue specimens express WTl (+KTS) isoforms, the expression of 
which correlates with wild-type p53. Interestingly, lower grade gliomas, including those 
of oligodendroglial origin, also express WTl. Unexpectedly, we found that WTl does not 
protect against p53-mediated apoptosis induced by either transient transfection with wild- 
type p53 or ionizing radiation. We also show that WTl silencing using transient siRNA 
transfection increases radiosensitivity of glioma cell lines. This is a finding that transcends 
the field of neuro-oncology as it has not, to our knowledge, been reported in any other type 
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of cancer. We utilized retroviral transduction with shRNA to stably inhibit WTI 
expression which caused a decrease in proliferation and invasion in vitro. Furthermore, 
glioblastoma cells stably expressing WT1 shRNA demonstrated decreased in vivo growth 
rate in nude mice. To date, no other studies have shown that WTl silencing causes 
decreased in vivo growth of cancer cells. We, therefore, have conclusively demonstrated 
for the first time that WTI plays a major role in the tumorigenicity and resistance to 
treatment of glioblastoma. 
While several other studies have conclusively shown that WT1 physically and 
functionally interacts with p53[136, 137, 871, we were unable to show such an interaction. 
It could be argued that utilization of a different model of p53 induction could have yielded 
superior results. However, in our studies we used both artificial (transient transfection) 
and endogenous (ionizing radiation) methods to induce a p53 response. In both cases, cells 
underwent cell death in response to p53 activation. Both of these sets of experiments 
failed to show a modulation of p53-mediated cell death by WTI expression. In addition, 
we attempted to use an LN-Z308 glioblastoma derived cell line stably expressing wild-type 
p53 under the control of a doxycycline-inducible promoter[243]. Induction of p53 with 
doxycycline resulted in upregulation of p53 protein, with no resultant decrease in viability 
or detectable cell cycle arrest, thus negating its utility in studying a WTlIp53 interaction 
(Appendix C). A potential alternative method of p53 overexpression is adenoviral 
transduction which effectively induces apoptosis in glioblastoma cells[68], however this 
was not used in this study. Nevertheless, based on the variety of techniques and cell 
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backgrounds tested in our studies, it is not probable that WT1 interacts functionally with 
p53 in relation to cell viability in glioma cells. 
We also showed that, while WT1 overexpression in WTl non-expressing p53 wild- 
type glioblastoma cells (U87MG) did not affect radiosensitivity, WT1 silencing in WTl- 
expressing glioblastoma cells increased radiosensitivity. We also generated glioblastoma 
cells of different p53 status (LN-229, p53 mutant; LN-Z308, p53 null) stably expressing 
WTl and also found no difference in radiosensitivity, suggesting that the lack of WT1 
induced radioresistance is applicable in general to glioma cells (Appendix D). An 
explanation is that, when dealing with an aggressive transformed cell that is maximally 
resistant to therapies, it is unlikely that the addition of one factor, such as WTl expression, 
will cause an increase in resistance. This is particularly true in a complex disease process 
such as glioblastoma in which several overlapping pathways contribute to radioresistance. 
In this situation, it is more feasible to decrease resistance by silencing a gene that is 
partially responsible for the resistance as we showed in our studies. The question as to 
how WTI mechanistically contributes to radioresistance remains unanswered. Our studies 
suggest that it is not due to interaction with p53 and subsequent inhibition of p53-mediated 
apoptosis. 
Thus, although these studies clearly support an oncogenic role of WT1 in 
glioblastoma, the mechanism by which it functions remains unknown. As mentioned 
above, in breast cancer cells WT1 transactivates c-myc which is known to promote 
proliferation[76]. Because c-myc is also overexpressed in glioblastoma, we examined the 
effect of WT1 silencing on c-myc protein expression by western blot and detected no 
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difference in U25 1 .Sh cells relative to U25 1 .VC (Appendix E). There exist several other 
candidates for mediators of the WTl effect on proliferation. EGF family members and 
EGFR are known WT1 targets[l27, 1241. They play a critical role in glioblastoma 
biology, in part by stimulating proliferation. In glioblastoma tissue, amplification and 
mutation are the most common causes of EGFR hyperactivity. However, in established 
glioma cell lines, EGFR amplification and EGFRvIII mutation are generally lost. Only 
one described cell line exhibits EGFR amplification[233]. Therefore, other mechanisms of 
up-regulation and activation of EGFR may be relevant to glioma cell behavior in culture. 
WT1 transactivation of EGFR could be a potential mechanism. Likewise, WT1 mediated 
up-regulation of EGFR stimulating ligands, such as Amphiregulin, may be responsible. 
Likewise, in certain settings WT1 activates PDGF, a known regulator of glioblastoma 
proliferation[255]. Unlike EGFR, amplification and/or mutation of PDGFR and its ligands 
are rare events. The mechanism of PDGF overexpression in glioblastoma is currently 
unknown. Future examination of the relationship between WTl and PDGF in gliomas 
may uncover an unrecognized mechanism of PDGF upregulation. 
The decrease in viability observed in cells transduced with WT1 shRNA could also 
be due to increased apoptosis due to WTl silencing. As previously described, WT1 up- 
regulates the anti-apoptotic protein Bcl-2 and may also regulate apoptosis via the pro- 
apoptotic protein Bax[144, 931. Again, we performed western blot analyses of U25 1.VC 
and U25 1 .Sh cell lysates and did not detect any difference in these proteins (Appendix E). 
Other potential mediators of apoptosis potentially modulated by WT1 are pro-apoptotic 
Bak and the anti-apoptotic Bcl-2 family member Al/BFL1[93,225]. Most of these studies 
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were performed in leukemia cells which undergo apoptosis much more readily than 
glioblastoma cells and, therefore, may display distinct patterns of gene expression in 
response to pro-apoptotic stimuli. We have not yet performed apoptosis analysis of these 
cells to determine the effect of WT1 silencing. 
We detected a significant decrease in glioblastoma cell invasion following WT1 
silencing. Glioblastoma cell invasion and destruction of normal brain continues to be one 
of the most difficult components in the clinical management of the disease. To date, no 
studies have examined the role of WTl in glioma invasion and few have examined its role 
in invasion in other types of cancer. The few studies in other cell types have yielded 
mixed results. A recent study demonstrates that WT1 overexpression in TYK ovarian 
cancer cells leads to increased motility and invasion[95]. This increase in invasion is 
associated with changes in cytoskeletal proteins, but a direct mechanism of WTl f~~nct ion 
is not described. In NIH-3T3 fibroblasts, WTl overexpression leads to up-regulation of E- 
cadherin[85]. This observation contrasts with our results and those of the previous study 
as E-cadherin loss is associated with increased invasion, therefore WT1 mediated 
transactivation of E-cadherin would be expected to decrease invasion. When interpreting 
the applicability of these studies, it is important to consider the cell-type dependence of 
WTl transcriptional activity. Because the MT2-MMP promoter contains several WTl 
binding sites and is relevant to glioma invasion, we examined the expression of MT2- 
MMP after WT1 silencing (Appendix E). We found no change in the levels of MT2-MMP 
protein. Screening of other MMPs relevant to gliomas is currently underway in the 
laboratory. 
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The role of WTl in glioblastoma may be more far-reaching than examined in this 
set of studies. As we detected WTl expression in astrocytomas of all grades, it is possible 
that WTl is also functioning at earlier stages of gliomagenesis. In the study of the earliest 
stages of gliomagenesis, an important question is the cell of origin of glioblastoma. The 
determination of the cell of origin has been difficult, particularly since the discovery of 
adult neural progenitor cells capable of proliferating and differentiating into the mature 
cells of the brain and, therefore, hypothetically able to undergo malignant transformation to 
form a glioblastoma[l94]. A theory which incorporates these ideas posits that 
astrocytomas arise from mature astrocytes that dedifferentiate into highly proliferative 
immature cells in response to genetic mutations. Recent evidence in mouse models 
supports this theory. Uhrbom et a1 report increased frequency of glial fibrillary acidic 
protein (GFAP) positive brain tumors with histologic features of glioblastoma in transgenic 
6rnk4a-Arf null mice in which mature astrocytes were specifically infected with a virus 
containing Akt and Ras[242]. These data suggest that a combination of genetic changes 
can induce dedifferentiation of astrocytes which are then capable of forming glioblastoma. 
Given that WT1 is preferentially expressed by undifferentiated leukemia and breast cancer 
specimens[l85,223], WTl overexpression decreases differentiation in leukemia cell 
lines[91,229,3,44], and WTI inhibition causes differentiation in the breast cancer cell 
lines[239], it seems probable that WTI functions in some cancer types to maintain the 
undifferentiated phenotype. In fact, several WT1 target genes have been shown to induce 
dedifferentiation in astrocytes and subsequent tumor formation. Viral transduction of the 
proto-oncogene c-myc in combination with Akt and Ras dedifferentiates astrocytes in 
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culture and increases glioblastoma formation when used to infect mature astrocytes in 
vivo[122]. WT1 transactivates c-myc as described above, however we showed that WTl 
silencing in U251MG cells did not effect levels of c-myc protein. This represents an 
observation in one glioblastoma cell line and needs to be replicated in others before a 
generalization can be made. In contrast to the previous examples which required 
combinations of gene transduction for dedifferentiation, infection of mature astrocytes with 
PDGF caused recapitulation of the undifferentiated phenotype in vitro and increased tumor 
formation in vivo[35]. As discussed previously, PDGF is a WT1 target gene and, similarly 
to WT1, is expressed at an early stage in gliomagenesis. One can envision a mechanism 
by which WT1 is aberrantly overexpressed by unknown factors which leads to 
transactivation of c-myc and PDGF causing dedifferentiation of mature astrocytes and 
maintenance of the immature phenotype. The affect of WT1 on astrocyte differentiation 
has not been studied, but it would be interesting to determine the outcome of WT1 
transfection into mature astrocytes alone or in combination with other genes. 
Future directions 
Athymic nude mice have been used successfully for decades to model human 
tumor growth when inoculated subcutaneously with tumor cells[189]. This model has 
provided invaluable data regarding tumor cell proliferation and efficacy of novel treatment 
modalities. There are, however, several major limitations to this type of animal model, 
particularly when applied to brain tumors such as glioblastoma. First is the absence of the 
unique environment of the brain. Second is the lack of invasion of tumor cells into the 
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normal tissue. Third is the lack of immune response. Future studies should include 
models which are compatible with the examination of these important components. 
Numerous studies have used U25 1 MG heterotopic subcutaneous xenografts to 
model human glioblastoma growth in vivo[155, 1031. Although the U25 1MG glioblastoma 
cell line was used to inoculate nude mice subcutaneously in the flank, this cell line 
possesses tumorigenic capacity in nude mouse brains also[204]. Future studies should 
focus on replicating the subcutaneous flank tumor growth data in mice inoculated 
orthotopically with U25 1MG cells stably expressing WT1 shRNA in .the caudate nucleus. 
In this model, the animal is followed until onset of neurological decline, at which time the 
animal is euthanized and the intracranial tumor is examined. The data is reported as 
survival after inoculation. After replication of the data using stable cell lines, more 
therapeutically relevant methods of knock-down should be tested. Our data demonstrating 
a decrease in tumor growth by stable expression of WT1 shRNA provides proof of 
principle that down-regulation of WT1 decreases in vivo tumor growth. A more stringent 
test of therapeutic potential is decreased growth rate or tumor regression after infusion of 
WTl shRNA, which more closely mimics the clinical scenario. Our laboratory has 
extensive experience in the study of therapeutic delivery modalities in the brain which 
could be combined with our use of WTl shRNA[15, 1901. Recently, direct intratumoral 
injection of shRNA plasmid expression vectors into established intracranial gliomas has 
induced down-regulation of target genes and subsequently affected tumor regression[69]. 
Replication of these results using WT1 shRNA would be a major step toward a potential 
clinical trial. 
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Studies examining the behavior of glioma cell lines and the tumor from which they 
were derived show that in vitro invasion assays correlate well with in vivo 
invasiveness[29]. This suggests that in vitro assays are valid models for studying glioma 
invasion. Nevertheless, it is critical to test anti-invasive therapies in vivo to better 
extrapolate efficacies in animal models to the clinical setting. Unfortunately, orthotopic 
xenografts of established glioblastoma cell lines grow as discrete masses that compress, 
but do not invade the mouse brain. Recently developed nude mouse models generate 
tumors which more closely recapitulate the invasive characteristics of human glioblastoma. 
Researchers obtain tissue biopsies during glioblastoma resections, process the fresh 
specimens, and immediately implant the suspension in the flanks of nude mice. After 
several heterotopic passages in nude mice, the tumors are excised and cultured briefly. 
Inoculation of the resulting cultures orthotopically in nude mice brains produces densely 
cellular, mitotically active, and rapidly lethal tumors characteristic of malignant 
astrocytomas[61]. The study also shows that the tumors retained several genetic 
characteristics of the patient tumors, including EGFR amplification. The tumors also 
readily invaded the host brain along white matter tracts in some cases leading to 
leptomeningeal spread and in one case gliomatosis cerebri mimicking the human disease. 
A follow-up study demonstrates the utility of the model. Using this model, EGFR 
inhibition combined with radiation therapy caused increased survival[206]. After 
characterization of the xenografts for WT1 expression, an experiment could be designed to 
examine the efficacy of WTl silencing strategies in decreasing in vivo glioma invasion. 
148 
The models described above utilize immunodeficient mice to study the behavior of 
human glioblastoma cells in vivo, but preclude the examination of the dynamic immune 
response in brain tumor biology. Recent studies suggest, however, that the immune system 
plays an important role in gliomagenesis. Scliwartzbaum et a1 report an inverse correlation 
between asthma and other allergic conditions and glioblastoma in a large case-control 
study[213]. In addition, they screened patients for polymorphisms in 5 genes known to be 
involved in both allergic conditions and glioma or brain biology. They found that 
polymorphisms in the pro-inflammatory genes interleukin receptor-4a (IL-4A) and 
interleukin- 13 (IL- 13) were inversely correlated with glioblastoma and positively 
correlated with asthma, suggesting that modulation of pro-inflammatory responses confers 
risk of glioma developnlent. Animal studies in immunologically intact rats suggest that 
these molecules may increase the immune system response to experimental gliomas. 
Therefore, study of gliomas must include analysis of immune function. In vitro and in vivo 
models exist to study and modulate the immune response to glioblastoma. Since WT1 is 
expressed by the majority of glioma specimens and not by normal cells, it is an attractive 
target for immunotherapy. Several mouse and rat brain tumor cell lines exist that could be 
utilized to study the immune response to WTl expressing tumors. These cell lines could 
be characterized for WT1 expression. An animal could then be immunized with WT1 
peptide plus adjuvant or WT1-pulsed antigen presenting cells after which the animal is 
challenged either subcutaneously or intracranially with the WT1 expressing tumor cell to 
determine if the tumor is rejected. 
149 
In spite of a lack of supportive animal data in glioblastoma, a clinical trial is 
underway to examine the safety and preliminary efficacy of WTl peptide vaccination for 
the treatment of refractory WT1-positive glioblastoma. The group reports that in a sample 
of 5 glioblastoma patients, 1 demonstrated a partial response and 4 maintained stable 
disease during the 12 week treatment period with minimal toxicity[l61]. Despite a paucity 
of studies in experimental glioma, several studies have examined the efficacy of 
immunotherapy targeting WT1 in other malignancies. Cytotoxic T lymphocytes (CTL) 
generated against WTl peptide specifically lyse WT1 positive leukemia cell lines and 
patient samples but not those that do not express WT1[172]. This response is specific to 
undifferentiated leukemia cells which express a higher level of WT1 than either more 
differentiated leukemia cells or WT1 positive normal hematopoetic progenitor cells which 
are spared[55]. Mice vaccinated wit11 either WT1 peptide or WTl encoding plasmide 
DNA generated WTl specific CTL capable of killing WT1 expressing leukemia cells and 
induced immunity against tumor challenge without evidence of autoimmunity[182,238]. 
A small scale clinical trial involving 2 breast cancer, 10 lung cancer, and 14 leukemia 
patients consisted of vaccination with WTl peptide and evaluation for change in tumor 
size and adverse effects[l81]. Of the 20 patients available for evaluation, 12 demonstrated 
the following clinical responses; decrease in tumor size (breast cancer), decrease in tumor 
markers (lung cancer), decrease in blast cells (leukemia), or decrease in WT1 expression 
(leukemia). An additional 2 patients maintained stable disease. A recent report 
demonstrates that, although WT1 -specific CTL are present in draining lymph nodes of a 
small sample of patients with stage 1 or 2 breast cancer, they were not capable of killing 
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breast cancer cells without adjuvant stimulation[64]. Taken together, these results indicate 
that vaccination strategies to activate endogenous impaired WT1-specific immune cells can 
induce clinically detectable responses in patients with leukemia and solid tumors, 
including glioblastoma. 
Conclusion 
Here we have shown that the majority of gliomas express WT1 while remaining 
undetectable in normal human astrocytes. Functional studies demonstrated that WT1 is 
critical for glioblastoma cell proliferation, invasion, radioresistance, and in vivo tumor 
formation and growth. Future studies will undoubtedly discern the molecular mechanisms 
by which WT1 exerts these effects and most likely will uncover an expanded list of 
functions in glioma biology. As molecular diagnostic modalities become more refined and 
prevalent, WTl may possess clinical utility in glioblastoma diagnosis and treatment. 
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APPENDIX A 
Decrease in WT1 mRNA expression in T98G glioma cells after 24 hours of 
hypoxia. 
Rationale. HIF-1 a transactivates the WT1 promoter in osteosarcoma cells exposed to 
hypoxia[250]. Since HIF-la may play a critical role in the response of glioma cells to 
intra-tumoral hypoxia, we examined the response of the WTl gene to hypoxia[94]. 
Methods. Cells were plated at a density of 1 X lo6 cells in 100 mm2 sterile tissue culture 
dishes and incubated overnight for attachment. Cultures were then placed in a humidified 
portable isolation Chamber (Billups-Rothenberg), flushed with a gas mixture of 1% O2 
plus 5% CO2 plus 94%N2. A rate of 15 liters per minute was used to purge the 
chamber for 3 minutes which yielded a concentration of 3% 02 .  The entire chamber was 
incubated 37" C for 24 hours, after which RNA was extracted from the cells followed by 
real-time PCR analysis to detect WTl mRNA expression as described previously. 
Differences between (+)hypoxia and (-)hypoxia within each cell line was analyzed by 
Student's t-test. *denotes p = 0.0 14 
Results and discussion. T98G cells demonstrated a significant decrease in WT1 mRNA 
expression after exposure to hypoxic conditions while LN-18 cells demonstrated no 
change. This possibly indicates a cell-type specific difference in WT1 response to 
hypoxia, the mechanism of which is currently not known. 
T98 LN18 
Cell line 
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APPENDIX B 
Decrease in WT1 mRNA expression after neuronal differentiation of human NTera-2 
cells. 
Rationale. WTl is down-regulated in PC12 cells induced to differentiate into neurons by 
NGF which is functionally important because it may be directly responsible for the down- 
regulation of EGFR during the differentiation procells[l27]. In an effort to generalize this 
observation, we examined the expression of WTl during the neuronal differentiation of a 
different model system; retinoic acid induced differentiation of NTera-2 (NT-2) cells. 
Methods. NT2 cells were maintained in ATCC modified DMEM (ATCC cat #30-2002) 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. For 
differentiation, 2 X 1 o6 cells were seeded in a 75 mm2 flask and treated with 10 pM 
retinoic acid (RA) dissolved in DMSO. Cells were incubated at 37" C 5% C02  for four 
weeks with RA-containing media replaced three times a week. After four weeks of RA 
treatment, cells were replated at a dilution factor of 1 :6 in fresh 75 mm2 flasks and then 
incubated for 24 hours at 37" C. Cells were then mechanically dislodged and floating cells 
were replated on Matrigel (BD Biosciences) diluted 1 :60 in 100 mm2 plates. After a 24 
hour incubation period, cells were again mechanically dislodged and collected. 7.5 X 1 o6 
cells were replated on Matrigel coated plates and incubated in media containing the mitotic 
inhibitors cytosine arabinoside (1 pM), 5-fluoro-2'-deoxyuridine (10 pM), and uridine (10 
pM). After 1 week in culture, media was changed to media containing mitotic inhibitor 
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minus cytosine arabinoside, and maintained for 3 weeks. Cells were then trypsinized and 
replated in six well plates coated with poly-L-lysine. 
Results and discussion. WT1 mRNA was detectable in undifferentiated NT-2 cells but 
fell to undetectable levels after retinoic acid induced neuronal differentiation. This 
suggests that WTl may play a role in the differentiation process of NT-2 cells and PC12 
cells, and may therefore by important for neuronal differentiation. 
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APPENDIX C 
Lack of p53 response in LN-Z308 cells stably expressing doxycycline inducible p53. 
Rationale. To examine the effect of WTl on p53 mediated apoptosis and cell cycle arrest 
we utilized a glioma cell line expressing wild-type p53 under the control of an inducible 
promoter. 
Methods. LN-Z308 cells expressing p53 under the control of a doxycycline inducible 
promoter (LNZ.C2024, kindly provided by Dr. Erwin Van Meir) were plated at a density 
of 2 X 10' cells per well of a six well plate and allowed to attach overnight. Cells were 
then transfected as described previously with a mixture 0.5 pg plasmid expression vector 
containing WTl(+/+) or (-I+) isoforms and 3 p1 Lipofectamine2000 (Invitrogen). For 
viability analysis, the next day, cells were gently harvested by trypsin-EDTA treatment, 
counted, and re-plated in 96 well tissue culture plates at a density of 1 X 1 o3 cells per well. 
After a 24 hour incubation, cells were treated with doxycycline to induce p53 expression. 
Viability was analyzed at 1 and 3 days after induction by ATP-based viability assay (C). 
At 24 hours after doxycycline treatment, RNA and protein were extracted. WTl mRNA 
was expressed after transient transfection and was unaffected by doxycycline (A). WT1 
and p53 were expressed after transient transfection and doxycycline treatment (B). For cell 
cycle analysis, cells were treated with doxycycline in six well plates for 24 hours and 
harvested. Cells were stained with propidium iodide and analyzed by flow cytometry (D). 
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Surprisingly, p53 induction did not cause a change in either cell viability or cell cycle 
distribution. 
Results and discussion. Transient transfection of LNZ.C2024 cells with WT1 caused a 
dose dependent increase in WT1 mRNA expression (Figure A). Addition of doxycycline 
caused an increase in p53 expression which was not affected by WT1 transfection (Figure 
B). However, p53 expression did not induce and change in viability or cell cycle 
distribution (Figures C and D). We can conclude that LNZ.C2024 cells possess a 
functional inactivation of p53. The mechanism is not known. 
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APPENDIX D 
Appendix D. WT1 expression does not protect LN-229 or LN-Z308 cells from 
ionizing radiation induced cell death. 
Rationale. We examined the effect of WT1 overexpression on radiosensitivity in LN-229 
and LN-Z308 cells. 
Methods. For protein extraction, LN-229 and LN-Z308 glioblastoma cells stably 
expressing WT1 (+I+) or (-I+) isoforms were plated at a density of 1 X 1 o6 cells/100 mm2 
plate and exposed to 6 Gy of ionizing radiation. 24 hours after irradiation, protein was 
extracted and Western blotting performed as described above. For ATP-based viability 
assay, 1 X 1 o3 cells were plated per well of 96 well flat bottom tissue culture plates and 
exposed to 6 Gy of ionizing radiation. Cells were lysed and viability extrapolated based on 
ATP content at 1,3,5,  and 7 days after irradiation. Results are reported as % viability of 
irradiated cells relative to matched non-irradiated cells. All treatment groups were 
performed in quintuplicate. 
Results and discussion. A. Western blotting demonstrates that LN-229 cells transfected 
with WT1 isoforms were stably expressing WT1 protein (top panel). WT1 expression did 
not change after irradiation. ATP-based viability assay demonstrated a time-dependent 
decrease in viability in LN-229 cells after irradiation (bottom panel). Stable WTl 
expression did not protect LN-229 cells from cell death. B. Similar results were obtained 
from LN-Z308 glioblastoma cells. C. ATP-based viability assays were repeated three 
times at the 7 day time point and demonstrated the same lack of protective effect of WT1 
213 
expression. We can conclude that in these two glioma cell lines, WT1 ovexpression does 
not protect agains ionizing radiation-induced cell death, 
1 3 5 7 
Days post-irradiation 
3 5 
Days post-irradiation 
LN-Z308 
Cell line 
APPENDIX E 
Changes in previously described WT1 targets are not responsible for 
decrease in proliferation and invasion after WT1 silencing 
Rationale. WTl decreases the proliferation of U25 IMG glioma cells in vitro and in vivo 
and may possibly affect in vitro invasion. In U25 1MG cells stably expressing WT1 
shRNA we examined the expression of known WTl target genes that were potentially 
involved in these processes. 
Methods. U25 1, U25 1 .VC, and U25 1 .Sh cells were plated at a density of 1 X 106 cells 
per 100 mm2 plate and allowed to attach overnight. The following day, protein was 
extracted by SDS lysis buffer as described previously. 20 pg of protein was separated by 
SDS-PAGE and transferred to nitrocellulose membrane. After blocking for 1 hour in 5% 
milk, membranes were incubated overnight at 4" C with anti-WT1 (1 :200, Dako 
Cytomation), anti-c-myc (1 : 100 dilution, Santa Cruz Biotechnology), anti-Bcl-2 (1 : 100, 
Calbiochem), anti-Bax (1 :300, Dako Cytomation), or anti-MT2-MMP (1 :2000, Chemicon). 
Membranes were washed six times with TBS-T and incubated with their corresponding 
secondary antibody for 1 hour at room temperature; anti-rabbit (1 :2000) for Bax and c- 
myc, anti-rabbit (1 5000) for MT2-MMP, anti-mouse (1 :2000) for Bcl-2, and anti-mouse 
(1 : 1000) for WT1. Membranes were again washed and protein was detected using the 
ECL detection system. 
Results and discussion. There were no significant differences in WTl target gene 
expression between U25 1 .VC and U25 1 .Sh protein lysates, suggesting that the decreases 
218 
in proliferation and invasion are due to WTl mediated changes in other targets that remain 
to be discerned. 
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